{
  "0YX.F": {
    "city": "Kobe",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Sysmex Corporation",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SYSMEX CORP.",
    "state": null,
    "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
    "website": "http://www.sysmex.co.jp",
    "zipcode": "651-0073"
  },
  "2137.S": {
    "city": "Sapporo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "SAP",
    "industry": "Medical Care Facilities",
    "long_name": "Hikari Heights-Varus Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HIKARI HEIGHTS-VARUS CO.LTD.",
    "state": null,
    "summary": "Hikari Heights-Varus Co.,Ltd. operates and manages nursing homes in Japan. Hikari Heights-Varus Co.,Ltd. was founded in 1987 and is headquartered in Sapporo, Japan.",
    "website": "http://www.varus.co.jp",
    "zipcode": "064-0919"
  },
  "2150.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "CareNet, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CARENET INC",
    "state": null,
    "summary": "CareNet, Inc. provides pharmaceutical sales support services for pharmaceutical companies in Japan. It offers medical content services for doctors and healthcare professionals. The company offers CareNet.com, a membership-based medical and medical information site for daily clinical practice; PubMedCLOUD, a tool for searching and managing PubMed articles in Japanese; Doctors'Picks, a site where doctors gather specialized news that they want their doctors to read; CareNeTV, a clinical medicine channel; CareNet DVD, a clinical medical education DVD teaching material; and CareNet Career, a service that guides candidates for work in response to the needs of CareNet members, such as doctors for changing jobs and seeking employment. It also provides MR Plus, a service that distributes medical information from pharmaceutical companies to CareNet doctor members via internet; and Web lecture, a service that live-streams lectures. The company was incorporated in 1996 and is based in Tokyo, Japan.",
    "website": "http://www.carenet.co.jp",
    "zipcode": "102-0074"
  },
  "2160.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "GNI Group Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GNI GROUP LTD",
    "state": null,
    "summary": "GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
    "website": "http://www.gnipharma.com",
    "zipcode": "103-0023"
  },
  "2183.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Linical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "LINICAL CO LTD",
    "state": null,
    "summary": "Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. It offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. The company also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. Linical Co., Ltd. was founded in 2005 and is headquartered in Osaka, Japan.",
    "website": "http://www.linical.co.jp",
    "zipcode": "532-0003"
  },
  "2191.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "tella, Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TELLA INC",
    "state": null,
    "summary": "tella, Inc. researches and develops regenerative and cell medicines. The company offers techniques and operational knowhow associated with dendritic cell vaccine therapy to affiliated medical institutions for the treatment of cancer. It is also involved in the provision of consultation services on the establishment and maintenance of cell processing centers, and on introduction of management systems for cell cultivation; and lease of standard operating procedure and regular checks on manufacturing operation management and training of cell cultivation technicians. In addition, the company provides consultation services on training of expertise regarding treatment practice; and support services for the assessment of therapies, documentation required for treatment practice, and cognition and information providing activities for physicians and patients. tella, Inc. was founded in 2004 and is based in Tokyo, Japan.",
    "website": "http://www.tella.jp",
    "zipcode": "160-0023"
  },
  "2309.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Diagnostics & Research",
    "long_name": "CMIC HOLDINGS Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CMIC HLDGS CO LTD",
    "state": null,
    "summary": "CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model. It offers clinical trial services, including clinical operations and trials, data management, in-country clinical caretaker services, medical writing, patient recruitment, pharmacovigilance, project management, audit and quality assurance, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance pricing, and product life cycle management consulting services. The company also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, technology transfer, as well as formulation, process, and analytical development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, it offers patient and healthcare services, such as drug adherence support program, harmo, Helc+, prescription drug database, and selcheck, as well as call center, medical affairs, and marketing authorization holder related services; and post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing, clinical research coordinating, clinical site administration, and site management services. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.",
    "website": "http://www.cmicgroup.com",
    "zipcode": "105-0023"
  },
  "2342.T": {
    "city": "Fukuoka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Trans Genic Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TRANS GENIC INC",
    "state": null,
    "summary": "Trans Genic Inc. develops, distributes, and licenses genetically engineered animals and antibodies in Japan. The company provides information of approximately 750 knockout mouse strains; 2,000 knockout ES clones produced by the exchangeable gene-trap method; 900 knockout mouse strains, as well as 750 phenotypic data centering on target genes for drug discovery. It also engages in the custom production of genetically engineered mice comprising conventional, conditional, and knock-in mice, as well as transgenic mice; and customized mouse-related analysis, such as speed congenics and phenotype analysis, including blood examination, as well as cryopreservation of embryo and sperm, and housing and breeding activities. In addition, the company provides mouse-related products, such as circadian locomotor output cycles kaput mice used as disease models; frozen embryos used to produce genetically engineered mice; and electronic instruction manual of reproduction technology for embryo manipulation, as well as approximately 600 antibody products. Further, it offers contract services for drug efficiency and pharmacological, safety pharmacological, disposition, and pharmacokinetic studies. Additionally, the company provides drug discovery support services, such as clinical and nonclinical pharmacological tests for Parkinson's and Alzheimer's diseases; and high density human tissue microarrays for use in the assessment of drug target molecules. It is also involved in the custom production of high-affinity, monoclonal, and polyclonal antibodies; and protein hyper-producing cells, as well as the provision of antibody purification and labeling, and peptide synthesis services. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was founded in 1998 and is headquartered in Fukuoka, Japan.",
    "website": "http://www.transgenic.co.jp",
    "zipcode": "810-0001"
  },
  "2370.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "MEDINET Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDINET CO LTD",
    "state": null,
    "summary": "MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. The company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was founded in 1995 and is headquartered in Tokyo, Japan.",
    "website": "http://www.medinet-inc.co.jp",
    "zipcode": "143-0006"
  },
  "2373.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Care Twentyone Corporation",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CARE TWENTYONE CORP",
    "state": null,
    "summary": "Care Twentyone Corporation provides nursing care services in Japan. The company offers visiting nursing, home nursing, home care support, and day care services. It also sells and rents welfare equipment; provides housing repair, light work contracting, education, temporary staffing, food service/food distribution dining, medical support, disability support, school lunch, childcare, and bus services; develops real estate; and offers marriage consultation brokerage services. The company was founded in 1993 and is headquartered in Osaka, Japan.",
    "website": "http://www.care21.co.jp",
    "zipcode": "530-0003"
  },
  "2374.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Saint-Care Holding Corporation",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SAINT-CARE HOLDING CORPORATION",
    "state": null,
    "summary": "Saint-Care Holding Corporation provides healthcare services in Japan. The company offers visiting care and nursing, visit bathing, short-stay daily-life care, small-scale and multifunction type in-home care, in-home long-term care management, and day care services; daily-life care services for the elderly with dementia; and personnel dispatch, outsourcing, and software services, as well as assisted living facilities. It also engages in the home renovation business; sale and rental of social welfare equipment; and care robot and other businesses. The company was founded in 1983 and is headquartered in Tokyo, Japan.",
    "website": "http://www.saint-care.com",
    "zipcode": "104-0031"
  },
  "2385.T": {
    "city": "Toyonaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Soiken Holdings Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SOIKEN HOLDINGS INC",
    "state": null,
    "summary": "Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives and other compounds. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. The company was founded in 1994 and is headquartered in Toyonaka, Japan.",
    "website": "http://www.soiken.com",
    "zipcode": "560-0082"
  },
  "2398.T": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Tsukui Holdings Corporation",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TSUKUI HOLDINGS CORP",
    "state": null,
    "summary": "Tsukui Holdings Corporation provides various home and nursing care services in Japan. It operates through four segments: Home Care, Pay Nursing Home, Assisted-Living Facilities, and Human Resource Development. The company offers day care services; and operates sheltered nursing homes. It also provides living quarters that offers daily-life support and nursing care services for elderly. In addition, the company provides worker dispatching and employment placement services primarily for the medical and nursing care sectors. Further, it is involved in the leasing of vehicles and various types of assistive devices; development of IoT, AI, robots, etc. for the nursing, welfare, and medical fields; and sale of merchandise comprising nursing care related equipment and supplies, such as diapers and wheelchairs through the Internet shopping malls. As of March 31, 2019, the company operated 692 facilities. The company was formerly known as Tsukui Corporation and changed its name to Tsukui Holdings Corporation in September 2020. Tsukui Holdings Corporation was founded in 1969 and is headquartered in Yokohama, Japan. As of March 24, 2021, Tsukui Holdings Corporation operates as a subsidiary of MBKP Life LLC.",
    "website": "http://www.tsukui-hd.co.jp",
    "zipcode": null
  },
  "2413.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "M3, Inc.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "M3 INC",
    "state": null,
    "summary": "M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates m3.com, a members-only Web site for providing information to the healthcare professionals; and MR-kun that delivers medical and drug information online through m3.com. It also provides MDLinx that offers the review of medical articles and theses in English for physicians in the United States; and MEDI:GATE, which provides various medical news and content, and features online discussion boards where doctors can exchange opinions and communicate with one another in South Korea. In addition, the company offers various Internet-based services for pharmaceutical and other medical-related companies, including marketing support services for medical solution providers and healthcare professionals, clinical trial services, clinical trial support services, market research services, and doctor and pharmacist recruiting support services. Further, it provides services for general public, such as the operation of AskDoctors, a Q and A site to consult doctors through the Internet; Ichie Websites comprising Ichie Breast Cancer and Ichie Menopause, which offers insights and solutions related to breast cancer and menopause; and iTicket Plus, a reservation system for clinics through mobile phones and the Internet. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was founded in 2000 and is headquartered in Tokyo, Japan.",
    "website": "http://corporate.m3.com",
    "zipcode": "107-0052"
  },
  "2435.T": {
    "city": "Kitakyushu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "CEDAR.Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CEDAR. CO LTD",
    "state": null,
    "summary": "CEDAR.Co.,Ltd. provides nursing care and rehabilitation services in Japan. It offers day care, resident life care, home-visit nursing care, home help, home care support, group home, and short term residency care services. The company was founded in 1981 and is headquartered in Kitakyushu, Japan.",
    "website": "http://www.cedar-web.com",
    "zipcode": null
  },
  "2664.T": {
    "city": "Oyama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Cawachi Limited",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CAWACHI LIMITED",
    "state": null,
    "summary": "Cawachi Limited manages drugstores in Japan. The company retails pharmaceuticals, health foods, child care products, cosmetics, daily miscellaneous goods, general food products, confectionery products, etc. It also involved in the insurance business. The company operates 346 drugstores. Cawachi Limited was founded in 1967 and is headquartered in Oyama, Japan.",
    "website": "http://www.cawachi.co.jp",
    "zipcode": "323-0061"
  },
  "2689.T": {
    "city": "Okayama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "OLBA HEALTHCARE HOLDINGS, Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OLBA HEALTHCARE HLDGS INC",
    "state": null,
    "summary": "OLBA HEALTHCARE HOLDINGS, Inc. installs and operates medical device distribution management systems primarily in Japan. The company distributes evidence based medical devices to enhance hospital operation. It also sells and leases home nursing beds, wheelchairs, etc.; and supports home renovation and provides expert consultation services. In addition, the company supports healthcare practices through the provision of optimum medical devices; provides support and response to various medical needs; and proposes procurement efficiency enhancements for hospital operation improvement. Further, it supports the life science field, such as reagents and testing equipment; and enhancements in convenience of patients and operation of clinics. Additionally, it is involved in the import and export operations. The company was formerly known as Kawanishi Holdings, Inc. and changed its name to OLBA HEALTHCARE HOLDINGS, Inc. in January 2021. OLBA HEALTHCARE HOLDINGS, Inc. was founded in 1921 and is headquartered in Okayama, Japan.",
    "website": "http://www.olba.co.jp",
    "zipcode": "700-0907"
  },
  "2784.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "Alfresa Holdings Corporation",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ALFRESA HOLDINGS CORP",
    "state": null,
    "summary": "Alfresa Holdings Corporation, through its subsidiaries, engages in the wholesale, manufacture, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in japan. It engages in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies. In addition, it manufactures and markets active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices. Further, the company's medical-related business includes its dispensing pharmacy and other medical-related activities. Alfresa Holdings Corporation was founded in 2003 and is based in Tokyo, Japan.",
    "website": "http://www.alfresa.com",
    "zipcode": "100-0004"
  },
  "2796.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Pharmarise Holdings Corporation",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHARMARISE HOLDINGS CORPORATION",
    "state": null,
    "summary": "Pharmarise Holdings Corporation manages dispensing pharmacies in Japan. Its dispensing pharmacies provide patients with dispensing services based on prescriptions drawn up by medical institutions. The company also manages drug stores and convenience stores; and sells cosmetics. In addition, it is involved in the storage and management of medical examination records of patients on behalf of medical institutions; operation of medical mall; and provision of temporary help, and stationery and office furniture. As of June 1, 2018, the company operated 308 pharmacies. Pharmarise Holdings Corporation was founded in 1984 and is headquartered in Tokyo, Japan.",
    "website": "http://www.pharmarise.com",
    "zipcode": "164-0011"
  },
  "2928.S": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "SAP",
    "industry": "Pharmaceutical Retailers",
    "long_name": "RIZAP GROUP, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RIZAP GROUP INC",
    "state": null,
    "summary": "RIZAP GROUP, Inc. engages in beauty, health, and lifestyle related businesses in Japan. It is also involved in the body makeup business; production, wholesale, and retail business of interior goods; sales of cosmetics, beauty equipment, and health food; maternity/baby related business; franchise business for various miscellaneous goods; bag planning/manufacturing; wholesale and retail of recording media, mobile phone, music video software, audio-video related miscellaneous goods, etc.; and book, magazine, and newspaper publication businesses. In addition, the company provides medical institution consulting, marketing support, and medical peripheral services; contact, mailing, and logistics services; printing agency and multimedia advertising services; general commercial printing and special printing services; processes and sells electrical parts; produces and sells various packaging materials and display backlight condensers; and plans and sells sports equipment, such as soccer, futsal, athletics, running, basketball, rugby, baseball equipment, etc. Further, it engages in fitness, cafe, childcare, and soccer club management; wholesale of Japanese clothing, women's clothing, etc.; designing, manufacturing, and wholesale of twisted yarn; watch import and wholesale; real estate/general construction; internet mail order, general merchandise OEM, and production management businesses, as well as operates specialty chain stores that sells casual wear and miscellaneous goods. The company was formerly known as KenKou Corporation, Inc. and changed its name to RIZAP GROUP, Inc. in July 2016. RIZAP GROUP, Inc. was founded in 2003 and is headquartered in Tokyo, Japan.",
    "website": "http://www.rizapgroup.com",
    "zipcode": "169-0074"
  },
  "2OB.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Oncolys BioPharma Inc.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONCOLYS BIOPHARMA INC.",
    "state": null,
    "summary": "Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. The company operates in two segments, Pharmaceutical Business and Diagnostic Business. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2001, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs, devices, and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Geron Corporation, Medigen Biotechnology Corp., WONIK CUBE Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.",
    "website": "http://www.oncolys.com",
    "zipcode": "105-0001"
  },
  "2PD.SG": {
    "city": "Kawasaki",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "PeptiDream Inc.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "PeptiDream Inc. Registered Shar",
    "state": null,
    "summary": "PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company uses its Peptide Discovery Platform System platform for the development of peptides. PeptiDream Inc. has a collaboration with Merck & Co. Inc. for the discovery and development of peptide therapeutics capable of neutralizing the SARS-CoV-2 virus (COVID19) and potential coronavirus outbreaks; and a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was founded in 2006 and is headquartered in Kawasaki, Japan.",
    "website": "http://www.peptidream.com",
    "zipcode": "210-0821"
  },
  "3034.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Qol Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "QOL HOLDINGS CO LTD",
    "state": null,
    "summary": "Qol Holdings Co., Ltd., together with its subsidiaries, engages in dispensing pharmacy and business process outsourcing contracting businesses in Japan. The company operates dispensing pharmacies through one-on-one store opening based on one-on-one trust relationships with medical institutions. It also undertakes sales and marketing research activities for pharmaceutical companies; and provides temporary staff dispatch for pharmacists, nurses, registered sellers, registered dietitians, etc. In addition, the company offers clinical trial support services for pharmaceuticals and food products; support, monitoring, and technician dispatch services of managers for various processes, from planning of trial execution plans to monitoring, secretariat support, statistical analysis, and the presentation of conference papers; and publishing related services. The company was formerly known as Qol Co., Ltd. and changed its name to Qol Holdings Co., Ltd. in October 2018. Qol Holdings Co., Ltd. was founded in 1992 and is headquartered in Tokyo, Japan.",
    "website": "http://www.qolhd.co.jp",
    "zipcode": "105-8452"
  },
  "3046.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "JINS HOLDINGS Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "JINS HOLDINGS INC",
    "state": null,
    "summary": "JINS HOLDINGS Inc., through its subsidiaries, engages in the planning, production, distribution, and sale of eyewear and fashion accessories in Japan. It offers eyewear, such as eye glasses and lenses; and JINS MEME that enables visualization of the user's physical and mental state. The company also provides men's and women's accessories, including bags, hats, and other items; and engages in contracting business for agriculture works. It operates retail outlets in Japan, China, the United States, Taiwan, and Hong Kong. The company was formerly known as JINS Inc. and changed its name to JINS HOLDINGS Inc. in July 2019. JINS HOLDINGS Inc. was founded in 1988 and is headquartered in Tokyo, Japan.",
    "website": "http://www.jinsholdings.com/jp/ja/",
    "zipcode": "102-0071"
  },
  "3055.S": {
    "city": "Sapporo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "SAP",
    "industry": "Medical Distribution",
    "long_name": "Hokuyaku Takeyama Holdings,Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HOKUYAKU TAKEYAMA HOLDINGS INC",
    "state": null,
    "summary": "Hokuyaku Takeyama Holdings,Inc. engages in the wholesale of pharmaceutical products in Japan. It also sells medical devices, such as medical/facility equipment, image diagnostic equipment, optical equipment, artificial organ-related equipment, biological information-related equipment, physical therapy equipment, and examination equipment, as well as general-purpose products, such as syringes and orthopedic surgery. In addition, the company operates approximately 60 pharmacies in Hokkaido; and provides nursing care services, welfare equipment, and support services for operation of nursery schools in companies and hospitals, as well as operates housing for seniors. Further, it is involved in the ICT and related business, including providing business systems for medical institutions, such as hospitals, clinics, pharmacies, and nursing facilities; and management support services for medical institutions and dispensing pharmacies. Hokuyaku Takeyama Holdings,Inc. is based in Sapporo, Japan.",
    "website": "http://www.hokutake.co.jp",
    "zipcode": "060-0006"
  },
  "3079.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "DVx Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DVX INC.",
    "state": null,
    "summary": "DVx Inc. engages in the import/export of medical devices and related peripheral devices in Japan. The company sells arrhythmia-related products, such as cardiac pacemakers, implantable cardioverter defibrillators, electrode catheters, and ablation catheters. It also offers ischemia-related products, including excimer laser systems; RADPAD, which reduces scatter radiation exposure to medical personnel during fluoroscopy procedures; RADNEK that reduces scatter radiation exposure to the thyroid in medical personnel during fluoroscopy procedures; RADCAP, which reduces scatter radiation exposure to the head of medical personnel during fluoroscopy procedures; and resolution/resolution SD and wonder belt products. In addition, the company engages in the research, development, manufacture, sale, repair, and leasing of medical devices and related peripheral devices; provision of internal and external medical and medical device-related general consulting and services; and medical publishing and market research activities. DVx Inc. was founded in 1986 and is headquartered in Tokyo, Japan.",
    "website": "http://www.dvx.jp",
    "zipcode": "171-0033"
  },
  "3088.T": {
    "city": "Matsudo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Matsumotokiyoshi Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MATSUMOTOKIYOSHI HOLDINGS CO LT",
    "state": null,
    "summary": "Matsumotokiyoshi Holdings Co., Ltd. operates a chain of drug stores and insurance dispensing pharmacies in Japan. The company also provides wholesale, as well as management support services. It operates through a network of 1,717 retail stores in 47 prefectures in Japan. The company also operates 31 branches in Thailand; and stores in Taiwan. Matsumotokiyoshi Holdings Co., Ltd. was founded in 1932 and is headquartered in Matsudo, Japan.",
    "website": "http://www.matsumotokiyoshi-hd.co.jp",
    "zipcode": "270-8511"
  },
  "3098.T": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "cocokara fine Inc.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "COCOKARA FINE INC",
    "state": null,
    "summary": "cocokara fine Inc., through its subsidiaries, engages in the drugstore and pharmacy operations in Japan. It also provides nursing and at-home care services; and operates assisted living facilities. In addition, the company is involved in the retail of health and beauty care products; promotion of employment of people with disabilities; sale and leasing of nursing care equipment and remodel homes; and logistics and online shopping businesses. It operates approximately 1,300 stores. cocokara fine Inc. was founded in 2008 and is headquartered in Yokohama, Japan.",
    "website": "http://corp.cocokarafine.co.jp",
    "zipcode": "222-0033"
  },
  "30O.F": {
    "city": "Kawasaki",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "OncoTherapy Science, Inc.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONCOTHERAPY SCIENCE INC.",
    "state": null,
    "summary": "OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.",
    "website": "http://www.oncotherapy.co.jp",
    "zipcode": "213-0012"
  },
  "3141.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Welcia Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "WELCIA HOLDINGS CO LTD",
    "state": null,
    "summary": "Welcia Holdings Co., Ltd., together with its subsidiaries, operates a chain of drug stores with dispensing pharmacies in Japan. Its stores primarily sells OTC and food, dispensing, cosmetics, household goods, and other products. The company also offers counseling services and long-term care services; and operates at-home care services and residential care facilities. It offers its products through an e-commerce site. As of March 1, 2020, the company operated 2,025 domestic and 7 overseas stores. Welcia Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan. Welcia Holdings Co., Ltd. is a subsidiary of Aeon Co., Ltd.",
    "website": "http://www.welcia.co.jp",
    "zipcode": "101-0021"
  },
  "3148.T": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Create SD Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CREATE SD HOLDINGS CO LTD",
    "state": null,
    "summary": "Create SD Holdings Co., Ltd., through its subsidiaries, engages in drug store, dispensing pharmacy, and nursing care businesses in Japan. The company sells pharmaceuticals, cosmetics, food products, daily goods, etc. It also operates and manages nursing homes and functional training type day service centers, as well as provides cleaning services for shops and administrative assistance work, etc. The company was founded in 1998 and is headquartered in Yokohama, Japan.",
    "website": "http://www.createsdhd.co.jp",
    "zipcode": "225-0014"
  },
  "3151.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "Vital KSK Holdings, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VITAL KSK HOLDINGS INC",
    "state": null,
    "summary": "Vital KSK Holdings, Inc. engages in the wholesale of pharmaceutical products in Japan. The company is involved in the wholesale of veterinary drugs; agricultural chemicals, agricultural materials, etc.; and medical and nursing care equipment. It also engages in the pharmacy and nursing care businesses; transportation business; insurance agent and real estate management businesses; parking business; mail-order business of health-related products; and pharmacy dispensing business. In addition, the company offers medical management consulting services; and manufactures OTC drugs. The company was founded in 2009 and is headquartered in Tokyo, Japan.",
    "website": "http://www.vitalksk.co.jp",
    "zipcode": null
  },
  "3154.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Medius Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIUS HLDG CO LTD",
    "state": null,
    "summary": "Medius Holdings Co., Ltd. operates in the medical care industry in Japan. The company sells medical equipment, such as syringes, gauze, other necessary medical consumables, and advanced medical system; and provides repair, after-sales, and maintenance services for medical equipment to hospitals and other medical facilities. It is also involved in the sale and rental of nursing care and welfare equipment to hospitals, nursing care facilities, and general individuals; and sale and rental of on-board medical instruments for ambulance, AEDs, and other emergency supplies and equipment with high social needs. The company was formerly known as Kyowa Medical Holdings, Inc. and changed its name to Medius Holdings Co., Ltd. in October 2010. Medius Holdings Co., Ltd. was founded in 2009 and is based in Tokyo, Japan.",
    "website": "http://www.medius.co.jp",
    "zipcode": "104-0031"
  },
  "3341.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nihon Chouzai Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NIHON CHOUZAI CO LTD",
    "state": null,
    "summary": "Nihon Chouzai Co., Ltd. engages in the management of health insurance dispensing chain pharmacies in Japan. The company also manufactures and sells generic drugs to medical institutions and other pharmacies. In addition, it offers temporary staffing services for pharmacist; and employment services for physicians and registered sales personnel, and other healthcare professionals. Further, the company provides studies and research services for pharmaceutical companies and organizations; information and consulting services for industries associated with pharmaceuticals and healthcare; and other services. Nihon Chouzai Co., Ltd. was founded in 1980 and is headquartered in Tokyo, Japan.",
    "website": "http://www.nicho.co.jp",
    "zipcode": "100-6737"
  },
  "3391.T": {
    "city": "Sapporo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Tsuruha Holdings Inc.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TSURUHA HOLDINGS INC",
    "state": null,
    "summary": "Tsuruha Holdings Inc. operates drugstores in Japan. Its drugstores offer medicines and supplements, as well as health, beauty, and diet goods. The company operates approximately 1,600 stores. It also sells products through mail order and online shops. The company was founded in 1929 and is headquartered in Sapporo, Japan.",
    "website": "http://www.tsuruha-hd.co.jp",
    "zipcode": "065-0024"
  },
  "3417.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Ohki Healthcare Holdings Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OHKI HEALTHCARE HOLDINGS CO LTD",
    "state": null,
    "summary": "Ohki Healthcare Holdings Co.,Ltd. distributes pharmaceutical products, health foods, dairy products, cosmetics, and daily necessities. The company imports, exports, and sells pharmaceuticals, quasi-drugs, medical equipment, cosmetics, poisons and deleterious substances, drugs, reagents, measuring instruments, optical instruments, electrical products, communication equipment, veterinary drugs, veterinary medical equipment, pet supplies, feed, feed additives, textile products, sanitary products, beauty and health equipment, sports equipment, leisure goods, nursing goods, nursing convenience goods, toys, stationery, homes supplies, daily necessities, groceries, food additives, alcoholic beverages, rice grains, salt, and cigarettes. It also provides chemicals, fertilizers, pesticides, gardening supplies, and agricultural supplies, as well as engages in the warehousing, information processing systems, distribution system equipment, and software development activities. In addition, the company engages in the pharmacy/drug store management and dispensing service, and nursing service businesses; manufacture and sale of pharmaceuticals, quasi-drugs, cosmetics, health foods, killing agents, medical and sanitary products, soft drinks, medical skin care, health food, and miscellaneous goods. Further, it is involved in the manufacture and wholesale of environmental conservation products; and wholesale of food and contact products, cosmetics, and miscellaneous goods, as well as license application agency business. The company was founded in 1658 and is headquartered in Tokyo, Japan.",
    "website": "http://www.ohki-net.co.jp",
    "zipcode": "112-0013"
  },
  "3446.T": {
    "city": "Ibaraki",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "JTEC Corporation",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "JTEC CORPORATION",
    "state": null,
    "summary": "JTEC Corporation designs, manufactures, and sells X-ray mirrors for synchrotron facilities in Japan. Its X-ray mirrors are used for study in the pharmaceutical, electronic, material, food, beauty, and other fields. The company also designs, develops, manufactures, and sells automated cell culture systems, as well as automated systems in various fields. JTEC Corporation was founded in 1993 and is headquartered in Ibaraki, Japan.",
    "website": "http://www.j-tec.co.jp",
    "zipcode": "567-0086"
  },
  "3544.T": {
    "city": "Sapporo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Satudora Holdings Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SATUDORA HOLDINGS CO LTD",
    "state": null,
    "summary": "Satudora Holdings Co., Ltd. primarily operates drug stores under the Drugstore and Satsudra names in Japan. The company also operates realistic shops under the seatsudra name; and dispensing pharmacies. In addition, it develops, wholesales, imports, and exports goods, as well as purchases and sells daily goods, consumables, and miscellaneous goods. Further, the company is involved in the energy business. It serves individuals, stores, and corporations. The company operates seven dispensing pharmacies with drugstore. Satudora Holdings Co.,Ltd. was founded in 1972 and is headquartered in Sapporo, Japan.",
    "website": "http://satudora-hd.co.jp",
    "zipcode": "8003"
  },
  "3549.T": {
    "city": "Hakusan",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Kusuri No Aoki Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "KUSURI NO AOKI HOLDINGS CO LTD",
    "state": null,
    "summary": "Kusuri No Aoki Holdings Co., Ltd. engages in retailing and dispensing pharmaceuticals, cosmetics, and daily necessities in Japan. The company was founded in 1999 and is headquartered in Hakusan, Japan.",
    "website": "http://www.kusuri-aoki-hd.co.jp",
    "zipcode": "924-8510"
  },
  "3593.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Hogy Medical Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HOGY MEDICAL CO",
    "state": null,
    "summary": "Hogy Medical Co.,Ltd. manufactures and sells expendable medical supplies to healthcare facilities in Japan and internationally. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, including gowns, caps, underwear, drapes, packaged products, equipment covers, kurumu, towels, and accessories, as well as isolation gowns, caps, and masks for use in operating rooms, outpatient areas, hospital wards, and other areas; and Tigalyer, a multi-layer fabric. The company also provides sterilization products, such as hybrid Mekkin bags, hybrid Mekkin bags ID layered type, and autoclave forceps stand caps; Mekkin cards, which are detection cards used to judge the sterilization process when sterilizing in an autoclave; ethylene oxide gas cards that are detection cards used to judge the sterilization process when sterilizing using ethylene oxide gas; and indicator tapes for autoclave sterilization. In addition, it offers IC Tracer, a gauze control system that uses integrated circuit chips embedded in each gauze used during surgery, making each one traceable; ASRC, a product made of a foamed polyethylene sponge that provides flexibility and functionality for use in varying procedures and inosculations; and Securea, a polyurethane sponge for endoscopic surgery. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.",
    "website": "http://www.hogy.co.jp",
    "zipcode": "107-8615"
  },
  "3604.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Kawamoto Corporation",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAWAMOTO CORP",
    "state": null,
    "summary": "Kawamoto Corporation manufactures and supplies medical and hospital products primarily in Japan. The company offers surgical sponges for laparoscopic surgery; neurosurgical pads; oral care products, such as suction toothbrushes/sponges and oral care sponges; gauze swabs, laparotomy sponges, elastic net and tubular bandages, plaster of paris bandages, orthopedic bandages, and medical casting tapes; and adhesive plasters and pads, and plastic transparent and paper surgical tapes. It also provides disposable medical products, including syringes, needles, dental needles, scalp vein sets, infusion sets, stopcocks, cotton swabs, alcohol pads, and wooden tongue depressors; surgical blades, blood lancets, scalpels, guedel airways, resuscitation masks, urine drainage and leg bags, urine meters, and catheters; and surgical and examination gloves. In addition, the company offers medical equipment comprising sphygmomanometers, stethoscopes, and digital B.P. monitors; and sanitary and nursing products, hygiene and health-related products, baby's goods and toiletries, and light textile products. Kawamoto Corporation also exports its products to Asia, the Middle East, Africa, Europe, and North/South America. The company was formerly known as Kawamoto Bandage Material Co., Ltd. and changed its name to Kawamoto Corporation in 1996. Kawamoto Corporation was founded in 1914 and is headquartered in Osaka, Japan. Kawamoto Corporation is a subsidiary of Air Water Inc.",
    "website": "http://www.kawamoto-sangyo.co.jp",
    "zipcode": null
  },
  "3649.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "FINDEX Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "FINDEX INC",
    "state": null,
    "summary": "FINDEX Inc. engages in the research and development, manufacture, and sale of medical systems in Japan. The company's products include Claio, a medical imaging database management system for small, medium, and large size hospitals; and C-Note, a progress note system. It also offers DocuMaker, a document and data management system, which provides various input tools to enhance productivity in document creation; and GAP/GAP-screener, a gaze analyzing perimeter. In addition, the company develops applications for smart phone. It serves medical institutions, hospitals, and clinics. The company was formerly known as PSC Inc. and changed its name to FINDEX Inc. in November 2014. FINDEX Inc. was founded in 1985 and is headquartered in Tokyo, Japan.",
    "website": "http://www.findex.co.jp",
    "zipcode": "100-0004"
  },
  "3671.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "Softmax Co., Ltd",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SOFTMAX CO LTD",
    "state": null,
    "summary": "Softmax Co., Ltd provides Web type electronic medical charts and medical accounting systems in Japan. It offers Web type electronic medical record and ordering systems, health checkup systems, radiology department information systems, rehabilitation department systems, surgical department systems, and solution systems. The company was formerly known as Victor Keisanki Kyushu Hanbai Co., Ltd. and changed its name to Softmax Co., Ltd in 2001. Softmax Co., Ltd was founded in 1974 and is headquartered in Tokyo, Japan.",
    "website": "http://www.s-max.co.jp",
    "zipcode": "140-0001"
  },
  "3939.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "Kanamic Network Co.,LTD",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KANAMIC NETWORK CO LTD",
    "state": null,
    "summary": "Kanamic Network Co.,LTD provides medical and elderly care information sharing system that promotes community comprehensive care in Japan. It offers medical care and elderly care communications system that provides cloud information sharing system, which offers collaboration among interdisciplinary and inter-organizational professionals in in-home care, nursing, and elderly care with care report, service calendar, and face sheet functions. The company also provides elderly care business management system, which offers a lineup of elderly care software that supports various elderly care services/business classifications, including elderly care facilities, community comprehensive support centers, and in-home care support facilities. In addition, it offers childcare support system that provides community-wide support for raising children comprising information distribution, consultation, and child growth record functions. Further, the company provides communication and application services for the elderly care and medical care fields; systems integration and solutions; website creation and operational services; management and systems consulting services; paid job placement services; and education and training services. Additionally, it is involved in the planning, production, and sale of web contents, videos, and various sales promotion tools; and planning and conducting of lectures, seminars, academic meetings, etc. Kanamic Network Co.,LTD was founded in 2000 and is headquartered in Tokyo, Japan.",
    "website": "http://www.kanamic.net",
    "zipcode": "150-6031"
  },
  "3G6.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "GNI Group Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GNI GROUP LTD.",
    "state": null,
    "summary": "GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
    "website": "http://www.gnipharma.com",
    "zipcode": "103-0023"
  },
  "3NQ.F": {
    "city": "Kashiwa",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "NanoCarrier Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOCARRIER CO. LTD",
    "state": null,
    "summary": "NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company's product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan.",
    "website": "http://www.nanocarrier.co.jp",
    "zipcode": "277-0871"
  },
  "3YV.MU": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Health Information Services",
    "long_name": "Medley, Inc.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDLEY INC.",
    "state": null,
    "summary": "Medley, Inc. operates platforms for recruitment and medical businesses in Japan. It operates through three segments: Recruitment Platform Business, Medical Platform Business, and New Services. The company manages JobMedley, a human resource recruitment systems for medical and healthcare, and related businesses; CLINICS Telemedicine, a telemedicine system for patients and medical institutions; CLINICS, a cloud medical support system; and MEDLEY, a medical information service for patients, as well as Kaigo-no Honne, a Website to search nursing care facilities. It also develops medical accounting software, as well as conducts proof-of-concept testing for pharms. Medley, Inc. was founded in 2009 and is headquartered in Tokyo, Japan.",
    "website": "http://www.medley.jp",
    "zipcode": "106-6222"
  },
  "4151.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kyowa Kirin Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KYOWA KIRIN CO LTD",
    "state": null,
    "summary": "Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",
    "website": "http://www.kyowakirin.com",
    "zipcode": "100-0004"
  },
  "4172.T": {
    "city": "Okayama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "Towa Hi System Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TOWA HI SYSTEM CO LTD",
    "state": null,
    "summary": "TOWA Hi SYSTEM CO.,LTD. develops medical software solutions. It is involved in the research and development, sale, and support of dental electronic medical record integrated systems; and iPad and web applications, such as inspection/periodontal examination systems, interview systems, own expense estimation systems, and image management systems, etc. The company was founded in 1978 and is headquartered in Okayama, Japan.",
    "website": "http://www.towa-hi-sys.co.jp",
    "zipcode": "700-0971"
  },
  "4438.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "Welby Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "WELBY INC",
    "state": null,
    "summary": "Welby Inc. provides digital tools that assist patients and their family in medical treatment and prevention of progression of disease. The company offers marketing support services to pharmaceuticals; and health insurance society and government through its digital service platform and tool. It also provides Welby My Karte, an app for patients to share health data with health care professionals and family as a visualized chart, as well as offers medical data research services. The company was founded in 2011 and is based in Tokyo, Japan.",
    "website": "http://www.welby.jp",
    "zipcode": "103-0023"
  },
  "4480.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "Medley, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDLEY INC",
    "state": null,
    "summary": "Medley, Inc. operates platforms for recruitment and medical businesses in Japan. It operates through three segments: Recruitment Platform Business, Medical Platform Business, and New Services. The company manages JobMedley, a human resource recruitment systems for medical and healthcare, and related businesses; CLINICS Telemedicine, a telemedicine system for patients and medical institutions; CLINICS, a cloud medical support system; and MEDLEY, a medical information service for patients, as well as Kaigo-no Honne, a Website to search nursing care facilities. It also develops medical accounting software, as well as conducts proof-of-concept testing for pharms. Medley, Inc. was founded in 2009 and is headquartered in Tokyo, Japan.",
    "website": "http://www.medley.jp",
    "zipcode": "106-6222"
  },
  "4483.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "JMDC Inc.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "JMDC INC",
    "state": null,
    "summary": "JMDC Inc. provides medical statistics data services in Japan. The company offers medical field big data services; life insurance field big data services; support services for health insurance associations and local government health services; health data platform; and medical institution support services. It serves health insurance associations, pharmaceutical companies, life insurance companies, research institutions, etc. The company was founded in 2002 and is headquartered in Tokyo, Japan. JMDC Inc. is a subsidiary of Noritz Steel Machine Co., Ltd.",
    "website": "http://www.jmdc.co.jp",
    "zipcode": "105-0012"
  },
  "4502.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TAKEDA PHARMACEUTICAL CO LTD",
    "state": null,
    "summary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.",
    "website": "http://www.takeda.com",
    "zipcode": "103-8668"
  },
  "4503.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "4506.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Sumitomo Dainippon Pharma Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUMITOMO DAINIPPON PHARMA CO LT",
    "state": null,
    "summary": "Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.",
    "website": "http://www.ds-pharma.com",
    "zipcode": "541-0045"
  },
  "4507.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Shionogi & Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SHIONOGI & CO",
    "state": null,
    "summary": "Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with InveniAI, LLC.; Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.",
    "website": "http://www.shionogi.com",
    "zipcode": "541-0045"
  },
  "4512.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Wakamoto Pharmaceutical Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "WAKAMOTO PHARMACEUTICAL CO",
    "state": null,
    "summary": "Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.",
    "website": "http://www.wakamoto-pharm.co.jp",
    "zipcode": "103-8330"
  },
  "4516.T": {
    "city": "Kyoto",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nippon Shinyaku Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "NIPPON SHINYAKU CO",
    "state": null,
    "summary": "Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.",
    "website": "http://www.nippon-shinyaku.co.jp",
    "zipcode": "601-8550"
  },
  "4517.T": {
    "city": "Kobe",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Biofermin Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOFERMIN PHARMACEUTICAL CO",
    "state": null,
    "summary": "Biofermin Pharmaceutical Co., Ltd. manufactures and sells drugs and quasi-drugs in Japan. It offers drugs for the treatment of diarrhea, constipation, and stomach digestion; and veterinary medicines, pesticides and other chemicals, cosmetics, medical equipment, foods, beverages, food additives, feeds, feed additives, and various tests. The company was formerly known as Kobe hygiene Laboratory Co., Ltd. and changed its name to Biofermin Pharmaceutical Co., Ltd. in March 1949. The company was founded in 1917 and is headquartered in Kobe, Japan. Biofermin Pharmaceutical Co., Ltd. is a subsidiary of Taisho Pharmaceutical Co., Ltd.",
    "website": "http://www.biofermin.co.jp",
    "zipcode": "650-0021"
  },
  "4519.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "4521.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Kaken Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KAKEN PHARMACEUTICAL",
    "state": null,
    "summary": "Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.",
    "website": "http://www.kaken.co.jp",
    "zipcode": "113-8650"
  },
  "4523.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Eisai Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "EISAI CO",
    "state": null,
    "summary": "Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.",
    "website": "http://www.eisai.co.jp",
    "zipcode": "112-8088"
  },
  "4524.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Morishita Jintan Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MORISHITA JINTAN",
    "state": null,
    "summary": "Morishita Jintan Co., Ltd. produces and distributes pharmaceuticals, quasi drugs, medical devices, and food products in Japan. It operates through Healthcare Business and Capsule Business divisions. The Healthcare Business division manufactures and sells Jintan branded products, as well as engages in OEM/ODM of dietary supplements, cosmetics, foods, etc. The Capsule Business division is involved in the OEM/ODM of pharmaceuticals, foods, etc., as well as the development of industrial use capsules. The company was founded in 1893 and is headquartered in Osaka, Japan.",
    "website": "http://www.jintan.co.jp",
    "zipcode": "540-8566"
  },
  "4528.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Ono Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ONO PHARMACEUTICAL CO",
    "state": null,
    "summary": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.",
    "website": "http://www.ono.co.jp",
    "zipcode": "541-8564"
  },
  "4530.T": {
    "city": "Tosu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Hisamitsu Pharmaceutical Co., Inc.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "HISAMITSU PHARMACEUTICAL CO INC",
    "state": null,
    "summary": "Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan. The company provides analgesic / anti-inflammatory patches; athlete's foot / ringworm remedy products; allergy-only rhinitis drugs; eye drops; high cholesterol improving drugs; acne remedies; cooling sheets; and supporters for knee, waist, elbow, calf and ankle. It also provides cooling sprays; bactericidal antibacterial spray and deodorant spray; ship fixing sheet; adhesive plasters for magnetic products; skin care products; sweat sheet; massage roller gel and oil spray; thermal equipment, and dietary supplements. The company offers its products under the Salon pass, Salonship, Air Salon Pass, Fatus, Butena Rock, Allegra, Direct pasting, Choleston, Life Cera, Deco Deco Cool, Children Robin Eye Plus. Eye cool, MSM, and other brand names. It sells its products in North America, Central and South America, Asia, Oceania, the Middle East, Africa, and Europe. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.",
    "website": "http://www.hisamitsu.co.jp",
    "zipcode": "841-0017"
  },
  "4534.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Mochida Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MOCHIDA PHARMACEUTICAL CO",
    "state": null,
    "summary": "Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.",
    "website": "http://www.mochida.co.jp",
    "zipcode": "162-0845"
  },
  "4536.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Santen Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SANTEN PHARMACEUTICAL CO",
    "state": null,
    "summary": "Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.",
    "website": "http://www.santen.com",
    "zipcode": "530-8552"
  },
  "4538.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Fuso Pharmaceutical Industries,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "FUSO PHARMACEUTICAL INDUSTRIES",
    "state": null,
    "summary": "Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. It primarily offers dialysates for artificial kidneys. The company was founded in 1937 and is headquartered in Osaka, Japan.",
    "website": "http://www.fuso-pharm.co.jp",
    "zipcode": "541-0045"
  },
  "4539.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nippon Chemiphar Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NIPPON CHEMIPHAR CO",
    "state": null,
    "summary": "Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.",
    "website": "http://www.chemiphar.co.jp",
    "zipcode": "101-0032"
  },
  "4540.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Tsumura & Co.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TSUMURA & CO",
    "state": null,
    "summary": "Tsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines, as well as Kampo powdered extracts; and sale of pharmaceuticals and food products. The company was founded in 1893 and is headquartered in Tokyo, Japan.",
    "website": "http://www.tsumura.co.jp",
    "zipcode": "107-8521"
  },
  "4541.T": {
    "city": "Toyama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nichi-Iko Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NICHI-IKO PHARMACEUTICAL CO",
    "state": null,
    "summary": "Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Toyama, Japan.",
    "website": "http://www.nichiiko.co.jp",
    "zipcode": "930-8583"
  },
  "4543.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Terumo Corporation",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TERUMO CORP",
    "state": null,
    "summary": "Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, drug-eluting stents, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, flow diverters, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The General Hospital Company segment provides infusion pumps, syringe pumps, solution sets, syringes, I.V. solutions, pain management products, nutritious food, adhesion barriers, blood glucose monitoring systems, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, automated blood collection systems, automated blood component processing systems, pathogen reduction technology, automated centrifugal apheresis systems, cell expansion system, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.",
    "website": "http://www.terumo.co.jp",
    "zipcode": "151-0072"
  },
  "4544.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Diagnostics & Research",
    "long_name": "H.U. Group Holdings, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "H.U. GROUP HLDGS INC",
    "state": null,
    "summary": "H.U. Group Holdings, Inc., through its subsidiaries, primarily provides clinical laboratory testing services in Japan. Its clinical laboratory testing services include collecting consigned specimens of patients from hospitals, clinics, and other medical institutions; and conducting analyses and reporting the test results back to these institutions. The company provides testing services in the areas of endocrinology, oncology, plasma protein disorders, virology, immunoserology, immunohematology, blood coagulation system, biochemistry, drug analysis, genetics, human leukocyte antigen, cellular immunity, pathology, cytodiagnosis, and other medical scientific analysis. It also develops, manufactures, and sells in vitro diagnostic reagents and assay instruments for infectious diseases and tumors to medical institutions, commercial laboratories, and blood centers; provides healthcare related services, such as sterilizing and clinical trials support; and rents and sells nursing-care equipment and supplies. In addition, the company offers home-visit nursing and long-term care. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was founded in 1950 and is headquartered in Tokyo, Japan.",
    "website": "http://www.hugp.com",
    "zipcode": "163-0408"
  },
  "4547.T": {
    "city": "Matsumoto",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Kissei Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KISSEI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.",
    "website": "http://www.kissei.co.jp",
    "zipcode": "399-8710"
  },
  "4548.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Seikagaku Corporation",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SEIKAGAKU CORP",
    "state": null,
    "summary": "Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.",
    "website": "http://www.seikagaku.co.jp",
    "zipcode": "100-0005"
  },
  "4549.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Eiken Chemical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "EIKEN CHEMICAL CO",
    "state": null,
    "summary": "Eiken Chemical Co., Ltd. manufactures and sells clinical diagnostics and equipment in Japan. The company is involved in developing clinical diagnostic aids to various aspects of contemporary medicine, including biochemical, immunological, serological, dry chemical diagnosis, and automatic analyzers. It also develops and supplies OC-SENSOR, an automated immunochemical fecal test for detecting gastrointestinal bleeding associated with disorders, such as colorectal cancer, polyps, and diverticulitis. In addition, the company offers real-time turbidi meters, and homeothermal equipment; amplification kits and fluorescence detection reagents for research use; and detection kits. Further, it manufactures a range of products that are used in the field of microbiology; and provides other products comprising immunological and serological reagents. The company was formerly known as Nihon Eiyokagaku Co., Ltd. and changed its name to Eiken Chemical Co., Ltd. in 1969. Eiken Chemical Co., Ltd. was founded in 1939 and is headquartered in Tokyo, Japan.",
    "website": "http://www.eiken.co.jp",
    "zipcode": "110-8408"
  },
  "4550.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Nissui Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NISSUI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally. It offers in vitro diagnostics and medical devices; culture media for microbiological testing; products for antimicrobial susceptibility tests, microorganism identification, and immunological tests; and quality control serum, which is used for ensuring the accuracy of clinical diagnoses. In addition,, the company provides microbiological testing products for food poisoning detection; immunosorbent assays for the detection of allergies to food items, such as eggs, wheat, milk, shrimp, crabs, buckwheat, peanuts, etc.; and culture media and reagents for regenerative medicine. Further, it supplies testing agents and bulk products to diagnostic agent manufacturers; and CompactDry, a dry medium that is used for coliform counting for food manufacturers. The company was formerly known as Nissan Research Institute Co., Ltd. and changed its name to Nissui Pharmaceutical Co., Ltd. in 1962. Nissui Pharmaceutical Co., Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.",
    "website": "http://www.nissui-pharm.co.jp",
    "zipcode": "110-8736"
  },
  "4551.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Torii Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TORII PHARMACEUTICAL CO",
    "state": null,
    "summary": "Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CEDARTOLEN, a sublingual immunotherapy drug. Torii Pharmaceutical Co., Ltd. markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.",
    "website": "http://www.torii.co.jp",
    "zipcode": "103-8439"
  },
  "4552.T": {
    "city": "Ashiya",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "JCR Pharmaceuticals Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "JCR PHARMACEUTICAL CO",
    "state": null,
    "summary": "JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, regenerative medicines, and drug substances primarily in Japan. The company offers GROWJECT, a recombinant human growth hormone for the treatment of short stature; Agalsidase Beta BS I.V. Infusion, a biosimilar for agalsidase beta for the treatment of Fabry disease, a type of lysosomal storage disorder; and TEMCELL HS Inj, a therapeutic product using mesenchymal stem cells for the treatment of acute graft-versus-host disease. It also develops biosimilar products for the treatment of renal anemia. The company was founded in 1975 and is headquartered in Ashiya, Japan.",
    "website": "http://www.jcrpharm.co.jp",
    "zipcode": "659-0021"
  },
  "4553.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Towa Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TOWA PHARMACEUTICAL CO",
    "state": null,
    "summary": "Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.",
    "website": "http://www.towayakuhin.co.jp",
    "zipcode": "571-8580"
  },
  "4556.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "KAINOS Laboratories, Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KAINOS LABORATORIES",
    "state": null,
    "summary": "KAINOS Laboratories, Inc. develops, manufactures, markets, distributes, and imports/exports pharmaceuticals, diagnostic reagents, related chemical products, physical and chemical measurement instruments, medical supplies, nutrition supplements, foodstuff, animal feed, and related products in Japan. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-III plus Test Kit for automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. It also provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum; Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for use in detecting type a and type b influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.",
    "website": "http://www.kainos.co.jp",
    "zipcode": null
  },
  "4559.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Zeria Pharmaceutical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ZERIA PHARMACEUTICAL",
    "state": null,
    "summary": "Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.",
    "website": "http://www.zeria.co.jp",
    "zipcode": "103-8351"
  },
  "4563.T": {
    "city": "Ibaraki",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "AnGes, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ANGES INC",
    "state": null,
    "summary": "AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.",
    "website": "http://www.anges.co.jp",
    "zipcode": "567-0085"
  },
  "4564.T": {
    "city": "Kawasaki",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "OncoTherapy Science, Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONCOTHERAPY SCIENCE INC",
    "state": null,
    "summary": "OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.",
    "website": "http://www.oncotherapy.co.jp",
    "zipcode": "213-0012"
  },
  "4565.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Sosei Group Corporation",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SOSEI GROUP CORP",
    "state": null,
    "summary": "Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of tumors and metastatic castration resistant prostate cancer; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage to treat migraine and other severe headaches; PF-07081532 and PF-07054894, which are in Phase l for use in multiple therapeutic areas; HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial to treat neurological order; GPR35 agonist to treat inflammatory bowel disease; and KY1051, which is in preclinical stage for the treatment of immuno-oncology. It also offers HTL0016878, a muscarinic M4 receptor agonist, which is in Phase I clinical trial for the treatment of Alzheimer's disease; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial to treat endocrine disorders; GLP-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; H4 antagonist, which is in preclinical stage to treat atopic dermatitis; EP4 antagonist, which is in preclinical stage to mediate PGE2 immunosuppression; GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage to treat intestinal disorder; GPR52 agonist to treat of neurology disease; and PAR2 mAb for the treatment of atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab; PeptiDream Inc; Pfizer; AbbVie; Biohaven; GSK; AstraZeneca; Novartis; Genentech; Takeda Pharmaceutical Company Limited; and Metrion Biosciences Limited. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.",
    "website": "http://soseiheptares.com",
    "zipcode": "102-0083"
  },
  "4568.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO COMPANY LIMITED",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "4569.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "KYORIN Holdings, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KYORIN HOLDINGS INC",
    "state": null,
    "summary": "KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical, generic, and over-the-counter drugs in Japan and internationally. It operates through Ethical Pharmaceutical Business and Consumer Healthcare Business segments. The company's products primarily include Flutiform, a drug for the treatment of asthma; Lasvic, an oral quinolone synthetic antibacterial agent; Desalex, an antiallergic agent; Kipres, a product for the treatment of bronchial asthma and allergic rhinitis; NASONEX, an allergic rhinitis therapeutic agent; Uritos and Beova, which are therapeutic agents for overactive bladder; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Mucodyne, a mucoregulan drug; and MONTELUKAST KM, which are generic drugs for the treatment of bronchial asthma and allergic rhinitis. It also provides Milton, a baby bottle disinfectant; Rubysta, a disinfectant cleaner; hand hygiene and skincare products; and prescription medicines and quasi-drugs, diagnostics, and industrial chemicals. In addition, the company is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trials business. Further, its pipeline products include KRP-AM1977Y, a quinolone synthetic antibacterial agent; KRP-116D for the treatment of interstitial cystitis; KRP-108P for the treatment of bronchial asthma; and Ad-SGE-REIC for treating Malignant pleural mesothelioma. Additionally, the company's out-licensed products in pipeline comprise FPR2 agonist program and KRP-203. KYORIN Holdings, Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.kyorin-gr.co.jp/en",
    "zipcode": "101-8311"
  },
  "4571.T": {
    "city": "Kashiwa",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "NanoCarrier Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOCARRIER CO LTD",
    "state": null,
    "summary": "NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company's product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan.",
    "website": "http://www.nanocarrier.co.jp",
    "zipcode": "277-0871"
  },
  "4574.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Taiko Pharmaceutical Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TAIKO PHARMACEUTICAL CO LTD",
    "state": null,
    "summary": "Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs, including gastrointestinal drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; and quasi-drugs, such as Trumpet Intestinal Regulator BF for stomach distention, loose stools, and constipation. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as LISPASS Cleverin generator, a machine which emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. In addition, the company manufactures and sells bath additives and pyroligneous acids for horticultural use. It operates in Japan, China, Hong Kong, Taiwan, Thailand, Malaysia, Vietnam, Mongolia, the United States, and Canada. Taiko Pharmaceutical Co.,Ltd. was founded in 1946 and is headquartered in Osaka, Japan.",
    "website": "http://www.seirogan.co.jp",
    "zipcode": "550-0005"
  },
  "4575.T": {
    "city": "Numazu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "CanBas Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CANBAS CO LTD",
    "state": null,
    "summary": "CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. The company develops CBP501, a calmodulin modulator for the treatment of tumors. It also develops CBS9106, a small molecule reversible inhibitor of Exportin-1 that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was founded in 2000 and is based in Numazu, Japan.",
    "website": "http://www.canbas.co.jp",
    "zipcode": "410-0801"
  },
  "4577.T": {
    "city": "Toyama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Daito Pharmaceutical Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DAITO PHARMACEUTICAL CO.LTD",
    "state": null,
    "summary": "Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was founded in 1942 and is headquartered in Toyama, Japan.",
    "website": "http://www.daitonet.co.jp",
    "zipcode": "939-8567"
  },
  "4578.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HLDGS CO LTD",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "4579.T": {
    "city": "Nagoya",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "RaQualia Pharma Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RAQUALIA PHARMA INC",
    "state": null,
    "summary": "RaQualia Pharma Inc. engages in the research and development of pharmaceutical compunds worldwide. The company offers Tegoprazan for gastroesophageal reflux diseases; ziprasidone for treatment of schizophrenia; Galliprant for pain management of dogs; and ENTYCE for treatment of anorexia of dogs. It also provides Cyclooxygenase-2 Inhibitor that is in Phase I clinical trial for pain; and Grapiprant which is in phase I and II clinical trials for cancer immunotherapy, as well as in phase I clinical trial for indication of pain. In addition, the company is developing potassium-competitive acid blocker for gastro-esophageal reflux disease; 5-HT2B Antagonist that has completed Phase I clinical trial for the treatment of irritable bowel syndrome; 5-HT4 Partial Agonist for gastroparesis, functional dyspepsia, and chronic constipation; and Motilin Receptor Agonist for gastroparesis, functional dyspepsia, and post-operative ileus. Further, it develops Ghrelin Receptor Agonist for the treatment of cancer-related anorexia/cachexia syndrome and spinal cord injury constipation; Selective Sodium Channel Blocker; Specific Ion Channels; P2X7 Receptor Antagonist for neuropathic pain; and TRPM8 Blocker Compounds for neuropathic pain. Additionally, the company licenses and sells intellectual property for pharmaceutical compounds and candidate compounds for clinical development. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was founded in 2008 and is headquartered in Nagoya, Japan.",
    "website": "http://www.raqualia.co.jp",
    "zipcode": "450-0003"
  },
  "4581.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Taisho Pharmaceutical Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TAISHO PHARMACEUTICAL HLDG CO L",
    "state": null,
    "summary": "Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.",
    "website": "http://www.taisho-holdings.co.jp",
    "zipcode": "170-8655"
  },
  "4582.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "SymBio Pharmaceuticals Limited",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SYMBIO PHARMACEUTICALS LTD",
    "state": null,
    "summary": "SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology. It primarily develops anti-cancer agents. The company's Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. It also develops SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, the company develops SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with azacitidine to treat HR-MDS. Further, it develops SyB V-1901, an antiviral drug for the treatment of infectious diseases. The company primarily operates in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore. SymBio Pharmaceuticals Limited was founded in 2005 and is based in Tokyo, Japan.",
    "website": "http://www.symbiopharma.com",
    "zipcode": "105-0001"
  },
  "4583.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Chiome Bioscience Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CHIOME BIOSCIENCE INC",
    "state": null,
    "summary": "Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery and Development Business; and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline includes ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, neuroblastoma, etc.; CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, breast cancer (TNBC), etc.; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, colorectal cancer, etc.; and BMAA, an anti-semphorin3a antibody for treating diabetic macular edema. The company serves universities, research institutions, and pharmaceutical companies. Chiome Bioscience Inc. was founded in 2005 and is headquartered in Tokyo, Japan.",
    "website": "http://www.chiome.co.jp",
    "zipcode": "151-0071"
  },
  "4586.T": {
    "city": "Higashikagawa",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MedRx Co., Ltd",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDRX CO LTD",
    "state": null,
    "summary": "MedRx Co., Ltd, a pharmaceutical company, develops pharmaceutical drugs based on the transdermal absorption system in Japan. It develops medicines based on Ionic liquid transdermal system. The company's products pipeline include MRX-4TZT, which is in phase II; MRX-5LBT, which is phase III; MRX-10XT, which is in phase I; and MRX-7MLL, which is in pre-clinical stage. It also offers micro needle patches for delivery of vaccines and/or APIs through skin, as well as adhesive skin patches. The company was founded in 2002 and is headquartered in Higashikagawa, Japan.",
    "website": "http://www.medrx.co.jp",
    "zipcode": "769-2712"
  },
  "4587.T": {
    "city": "Kawasaki",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "PeptiDream Inc.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "PEPTIDREAM INC",
    "state": null,
    "summary": "PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company uses its Peptide Discovery Platform System platform for the development of peptides. PeptiDream Inc. has a collaboration with Merck & Co. Inc. for the discovery and development of peptide therapeutics capable of neutralizing the SARS-CoV-2 virus (COVID19) and potential coronavirus outbreaks; and a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was founded in 2006 and is headquartered in Kawasaki, Japan.",
    "website": "http://www.peptidream.com",
    "zipcode": "210-0821"
  },
  "4588.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Oncolys BioPharma Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONCOLYS BIOPHARMA INC",
    "state": null,
    "summary": "Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. The company operates in two segments, Pharmaceutical Business and Diagnostic Business. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2001, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs, devices, and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Geron Corporation, Medigen Biotechnology Corp., WONIK CUBE Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.",
    "website": "http://www.oncolys.com",
    "zipcode": "105-0001"
  },
  "4591.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Ribomic Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RIBOMIC INC",
    "state": null,
    "summary": "Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. It develops drugs in the areas of pain, heart failure, achondroplasia, osteoarthritis, osteosclerosis, and fibrosis, as well as age-related macular degeneration. Ribomic Inc. has a joint research and development agreement with ASKA Pharmaceutical Co., Ltd. for drug discovery research and development targeting specific hormone receptors. The company was incorporated in 2003 and is headquartered in Tokyo, Japan.",
    "website": "http://www.ribomic.com",
    "zipcode": "108-0071"
  },
  "4592.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "SanBio Company Limited",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SANBIO COMPANY LIMITED",
    "state": null,
    "summary": "SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
    "website": "http://www.sanbio.jp",
    "zipcode": "104-0044"
  },
  "4593.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Healios K.K.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HEALIOS KK",
    "state": null,
    "summary": "Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.",
    "website": "http://www.healios.co.jp",
    "zipcode": "100-0006"
  },
  "4594.T": {
    "city": "Kurume",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "BrightPath Biotherapeutics Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BRIGHTPATH BIOTHERAPEUTICS CO L",
    "state": null,
    "summary": "BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. It develops ITK-1, a cancer peptide vaccine, which is in Phase III clinical study to treat prostate cancer. The company is also developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. Its products in research stage include GRN-1301, a drug resistant tumor-derived neoantigen for the treatment of non-small cell lung cancer; and iPS-NKT, an induced pluripotent stem cell derived regenerated NKT cell therapy. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Kurume, Japan.",
    "website": "http://www.brightpathbio.com",
    "zipcode": null
  },
  "4595.T": {
    "city": "Tosu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Mizuho Medy Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MIZUHO MEDY CO LTD",
    "state": null,
    "summary": "Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products primarily in Japan. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including digital p-check test for OTC. The company also operates in the United States, Belgium, France, China, South Korea, Singapore, and Taiwan. Mizuho Medy Co.,Ltd. was founded in 1977 and is headquartered in Tosu, Japan.",
    "website": "http://www.mizuho-m.co.jp",
    "zipcode": "841-0048"
  },
  "4596.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Kubota Pharmaceutical Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KUBOTA PHARMACEUTICAL HLDGS CO ",
    "state": null,
    "summary": "Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing human rhodopsin-based gene therapy for patients suffering from retinitis pigmentosa; a lanosterol-based pharmaceutical treatment for cataracts and presbyopia; and a small molecule pharmacologic treatment for age-related macular degeneration, diabetic macular edema, and other retinal neovascular conditions. In addition, it is developing home-based, patient self-monitoring optical coherence tomography devices. The company was founded in 2002 and is based in Tokyo, Japan.",
    "website": "http://www.kubotaholdings.co.jp",
    "zipcode": "100-0013"
  },
  "4597.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Solasia Pharma K.K.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SOLASIA PHARMA K K",
    "state": null,
    "summary": "Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 (PledOx), an intracellular superoxide removing agent, which is in phase IIb clinical trials for chemotherapy induced peripheral neuropathy. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.",
    "website": "http://www.solasia.co.jp",
    "zipcode": "105-0011"
  },
  "4599.T": {
    "city": "Ibaraki",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "StemRIM",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STEMRIM INC",
    "state": null,
    "summary": "StemRIM, a biotechnology company, develops regeneration-guided medicines for the treatment of intractable diseases. The company focuses on the research and development of regeneration-inducing medicines that are applied to various diseases, such as epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, and stem cell gene therapy, as well as autologous cell collection devices for treatment. It also provides PJ1 regeneration induction medicine HMGB1 peptides, PJ2 regeneration induction drug new peptides, and PJ3 regeneration-inducing proteins derived from living bodies; PJ4 therapeutic autologous cell collection device; and PJ5 stem cell gene therapy technology. StemRIM was founded in 2006 and is headquartered in Ibaraki, Japan.",
    "website": "http://www.stemrim.com",
    "zipcode": "567-0085"
  },
  "4671.T": {
    "city": "Kyoto",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Diagnostics & Research",
    "long_name": "FALCO HOLDINGS Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "FALCO HOLDINGS CO LTD",
    "state": null,
    "summary": "FALCO HOLDINGS Co., Ltd., a medical service company, primarily provides clinical testing and dispensing pharmacy services to medical institutions and companies in Japan. It offers clinical testing services in the fields of genetic tests, biochemistry, hematology, pathology, immunology, microbiology, and radio immunoassay; genetic testing services; and genomic-based drug discovery and biotechnology drug development services. The company also provides medical information technology services; food sanitation and environmental testing services; and food related genetic testing services to food manufacturers, retailers, and restaurants. In addition, it is involved in the dispensing pharmacies and drugstores business; and development and sale of various medical information systems, including @home Dr. electronic medical charts for clinics with concentrated clinical testing, as well as TASCAL for ASP, a medical support system. The company was founded in 1962 and is headquartered in Kyoto, Japan.",
    "website": "http://www.falco-hd.co.jp",
    "zipcode": "604-0911"
  },
  "4694.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Diagnostics & Research",
    "long_name": "BML, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BML INC",
    "state": null,
    "summary": "BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis; microbiological tests for medical and pharmaceutical societies and organizations; and laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies. It also develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, and subsequent test procedures; and provides electronic medical charts for networking medical information, as well as offers preventive medicine services. In addition, the company provides food sanitation control and food processing services comprising contract services for microorganism testing of raw materials, and prepared and processed foods; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and waste water tests; work sanitation management services, such as measurement of ethylene oxide gas, formaldehyde, organic solvents, and dust; environmental monitoring services, including measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal diseases; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. BML, Inc. was founded in 1955 and is headquartered in Tokyo, Japan.",
    "website": "http://www.bml.co.jp",
    "zipcode": null
  },
  "4880.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "CellSource Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CELLSOURCE CO LTD",
    "state": null,
    "summary": "CellSource Co., Ltd. manufactures regenerative medicines. The company was founded in 2015 and is based in Tokyo, Japan.",
    "website": "http://www.cellsource.co.jp",
    "zipcode": "150-0002"
  },
  "4881.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "FunPep Company Limited",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "FUNPEP COMPANY LTD",
    "state": null,
    "summary": "FunPep Company Limited engages in the research and development of pharmaceuticals, cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, an intractable skin ulcer drug; FPP003, an antibody-inducing peptide that is in Phase I/IIa clinical study for the treatment of psoriasis in Australia, as well as is in preclinical studies for ankylosing spondylitis in Japan; and FPP004, an antibody-inducing peptide for pollinosis. The company was founded in 2013 and is based in Tokyo, Japan.",
    "website": "http://www.funpep.co.jp",
    "zipcode": "151-0051"
  },
  "4883.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Modalis Therapeutics Corporation",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MODALIS THERAPEUTICS CORP",
    "state": null,
    "summary": "Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology that enables the locus specific modulation of gene expression or histone modification without the need for double-stranded DNA cleavage, gene editing, or base editing. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.",
    "website": "http://modalistx.com",
    "zipcode": "103-0026"
  },
  "4884.T": {
    "city": "Ibaraki",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Kringle Pharma, Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KRINGLE PHARMA INC",
    "state": null,
    "summary": "Kringle Pharma, Inc., a pharmaceutical biotechnology venture company, engages in the research and development of hepatocyte growth factor (HGF) protein medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis (ALS), ALS acute kidney injury, and vocal fold scar. Kringle Pharma, Inc. was founded in 2001 and is based in Ibaraki, Japan.",
    "website": "http://www.kringle-pharma.com",
    "zipcode": "567-0085"
  },
  "4886.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "ASKA Pharmaceutical Holdings Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ASKA PHARMACEUTICAL HOLDINGS CO",
    "state": null,
    "summary": "ASKA Pharmaceutical Holdings Co., Ltd. engages in the manufacture, sale, and import/export of pharmaceuticals, veterinary medicines, quasi-drugs, foods, and medical devices in Japan. The company offers Altat for the treatment of peptic ulcer and gastritis; Prostal drugs for the treatment of prostatic hypertrophy and cancer; Lipidil for the treatment of hyperlipidemia; Thyradin, a drug for the treatment of thyroid disease; Ange, an oral contraceptive agent; and Menoaid Combipatch, a climacteric syndrome treatment. It is also developing L-105 for the treatment of hepatic encephalopathy; AKP-501, a fertility treatment with follicle stimulating hormone preparation of recombinant DNA as an active agent; and CDB-2914, a uterine leiomyomata treatment. The company was founded in 1920 and is headquartered in Tokyo, Japan.",
    "website": "http://www.aska-pharma.co.jp",
    "zipcode": "108-8532"
  },
  "4887.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Sawai Group Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SAWAI GROUP HOLDINGS CO LTD",
    "state": null,
    "summary": "Sawai Group Holdings Co., Ltd., together with subsidiaries, manufactures, sells, imports, and exports pharmaceutical products in Japan and the United States. The company offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. It serves hospitals, general practitioners, and dispensing pharmacies. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.",
    "website": "http://www.sawai.co.jp",
    "zipcode": "532-0003"
  },
  "4931.T": {
    "city": "Fukuoka City",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Shinnihonseiyaku Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SHINNIHONSEIYAKU CO LTD",
    "state": null,
    "summary": "Shinnihonseiyaku Co., Ltd. provides cosmetics, pharmaceuticals, and health foods in Japan and internationally. It operates through Mail Order, Direct Store Sales/Wholesale, and Overseas Sales segments. The company provides skincare products under the Perfect One brand; and pharmaceutical products for various diseases and symptoms. It operates a network of 12 stores; and online shops. The company was formerly known as Shinnihonliving Co., Ltd. and changed its name to Shinnihonseiyaku Co., Ltd. in April 2002. Shinnihonseiyaku Co., Ltd. was founded in 1992 and is headquartered in Fukuoka City, Japan.",
    "website": "http://www.corporate.shinnihonseiyaku.co.jp/",
    "zipcode": "810-0074"
  },
  "4974.T": {
    "city": "Kusatsu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Takara Bio Inc.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TAKARA BIO INC",
    "state": null,
    "summary": "Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.",
    "website": "http://www.takara-bio.com",
    "zipcode": "525-0058"
  },
  "4978.T": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "ReproCELL Incorporated",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "REPROCELL INCORPORATED",
    "state": null,
    "summary": "ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, and feeder cells; and 3D cell culture, labware, and drug discovery assays. The company also provides stem cell services, such as target cell isolation, iPSC reprogramming, and cell differentiation, as well as iPSC expansion, characterization, and banking services; and predictive drug discovery services in the areas of cardiac, vascular, respiratory, gastrointestinal, ADME/DMPK, skin/skin model, genitourinary, comparative pharmacology, and other assays. In addition, it offers human tissue samples, prospective collections, molecular, 3D cell, primary cell isolation, and DNA and RNA extraction services. ReproCELL Incorporated was founded in 2003 and is headquartered in Yokohama, Japan.",
    "website": "http://www.reprocell.com",
    "zipcode": "222-0033"
  },
  "4HN.F": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Pharmaceutical Retailers",
    "long_name": "cocokara fine Inc.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "COCOKARA FINE INC.",
    "state": null,
    "summary": "cocokara fine Inc., through its subsidiaries, engages in the drugstore and pharmacy operations in Japan. It also provides nursing and at-home care services; and operates assisted living facilities. In addition, the company is involved in the retail of health and beauty care products; promotion of employment of people with disabilities; sale and leasing of nursing care equipment and remodel homes; and logistics and online shopping businesses. It operates approximately 1,300 stores. cocokara fine Inc. was founded in 2008 and is headquartered in Yokohama, Japan.",
    "website": "http://corp.cocokarafine.co.jp",
    "zipcode": "222-0033"
  },
  "5187.T": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Create Medic Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CREATE MEDIC CO",
    "state": null,
    "summary": "Create Medic Co., Ltd. researches, manufactures, and sells medical appliances in Japan and internationally. The company offers disposable medical devices made of silicone resin. It provides various urology, gastroenterology, percutaneous endoscopic gastrostomy, and surgery products. The company also provides other products, such as CLINY tracheostomy tubes, endotracheal tubes, tracheostomy tubes, and micro catheters. In addition, it offers OEM products comprising multi-lumen tubes, ultrathin-walls, profile extrusions, and special structures; special shape and high-volume low-pressure cuff moldings; and hydrophilic coating and needles, as well as the technology on OEM basis. The company was formerly known as NASK Co., Ltd. and changed its name to Create Medic Co., Ltd. in July 1977. Create Medic Co., Ltd. was founded in 1974 and is headquartered in Yokohama, Japan.",
    "website": "http://www.createmedic.co.jp",
    "zipcode": "224-0037"
  },
  "59Z.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Distribution",
    "long_name": "MediPal Holdings Corporation",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MEDIPAL HOLDINGS CORP.",
    "state": null,
    "summary": "Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business. It also engages in delivering cosmetics, daily necessities, OTC pharmaceuticals, and other products; and animal health products and food processing raw materials wholesale business. In addition, it engages in the provision of cleaning management services; management and operation of distribution centers; planning, management, administration, and product and service development for the Class A dispensing pharmacy service brand; management and marketing support for dispensing pharmacies; and import/export wholesale distribution. Further, it offers health insurance claims review, medical coding dispatch, outsourcing, and remote education services; non-life insurance agency services; medical supply and master product databases for medical facilities; and commissioned delivery and worker dispatch services. The company serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. Medipal Holdings Corporation was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. The company was founded in 1898 and is headquartered in Tokyo, Japan.",
    "website": "http://www.medipal.co.jp",
    "zipcode": "104-8461"
  },
  "5F3.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "JINS HOLDINGS Inc.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "JINS HOLDINGS INC.",
    "state": null,
    "summary": "JINS HOLDINGS Inc., through its subsidiaries, engages in the planning, production, distribution, and sale of eyewear and fashion accessories in Japan. It offers eyewear, such as eye glasses and lenses; and JINS MEME that enables visualization of the user's physical and mental state. The company also provides men's and women's accessories, including bags, hats, and other items; and engages in contracting business for agriculture works. It operates retail outlets in Japan, China, the United States, Taiwan, and Hong Kong. The company was formerly known as JINS Inc. and changed its name to JINS HOLDINGS Inc. in July 2019. JINS HOLDINGS Inc. was founded in 1988 and is headquartered in Tokyo, Japan.",
    "website": "http://www.jinsholdings.com/jp/ja/",
    "zipcode": "102-0071"
  },
  "5FA.F": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nipro Corporation",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NIPRO CORP.",
    "state": null,
    "summary": "Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations. The company's Pharma Packaging business offers glass vials, ampoules, syringes, and cartridges; glass tubes; glass forming machinery; glass bulbs for vacuum flasks; and other parts of pharmaceutical packaging, such as rubber plugs. Its Other business provides thermostable enzymes for clinical chemistry. The company also offers business management services. Nipro Corporation serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.",
    "website": "http://www.nipro.co.jp",
    "zipcode": "531-8510"
  },
  "5FR.F": {
    "city": "Nagoya",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Menicon Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MENICON CO.LTD",
    "state": null,
    "summary": "Menicon Co., Ltd. manufactures and sells contact lenses and lens care products worldwide. It provides soft, GP, and specialty lenses. The company was incorporated in 1943 and is headquartered in Nagoya, Japan",
    "website": "http://www.menicon.co.jp",
    "zipcode": "460-0006"
  },
  "6029.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Artra Group Corporation",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ARTRA GROUP CORPORATION",
    "state": null,
    "summary": "Artra Group Corporation provides support services for acupuncture and osteopathic hospitals in Japan. The company offers billing services; and HONEY-STYLE, a system, which specializes in word-of-mouth/reservation system for acupuncture and moxibustion hospital. It also operates Atlas Store, an EC site that sells consumables for acupuncture and moxibustion hospital; and a portal site providing information for judo reduction teachers, acupuncturists/kyu teachers, and anma massage shiatsu teachers through its website and e-mail magazine, as well as offers nursing care services. The company was formerly known as artra corporation and changed its name to Artra Group Corporation in 2021. Artra Group Corporation was founded in 2005 and is headquartered in Osaka, Japan.",
    "website": "http://www.artra-group.co.jp",
    "zipcode": "550-0012"
  },
  "6059.T": {
    "city": "Kitakyushu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "UCHIYAMA HOLDINGS Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "UCHIYAMA HLDGS CO LTD",
    "state": null,
    "summary": "UCHIYAMA HOLDINGS Co.,Ltd. offers nursing care services in Japan. It is also involved in the real estate, karaoke, restaurant, and hotel businesses. The company was founded in 2006 and is headquartered in Kitakyushu, Japan.",
    "website": "http://www.uchiyama-gr.jp",
    "zipcode": "802-0044"
  },
  "6062.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Charm Care Corporation",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CHARM CARE CORPORATION",
    "state": null,
    "summary": "Charm Care Corporation engages in nursing care business. It operates fee-based nursing homes that offer nursing-assisted living care services. The company was formerly known as Fuji Clinic Laboratory and changed its name to Charm Care Corporation in December 2007. Charm Care Corporation was founded in 1984 and is headquartered in Osaka, Japan.",
    "website": "http://www.charmcc.jp",
    "zipcode": "530-0005"
  },
  "6063.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Emergency Assistance Japan Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EMERGENCY ASSISTANCE JAPAN CO L",
    "state": null,
    "summary": "Emergency Assistance Japan Co., Ltd. provides medical and lifestyle assistance services in Japan and internationally. It also offers security assistance program, student security management assistance, and emergency response services, as well as assistance services for foreign nationals. The company was founded in 2003 and is headquartered in Tokyo, Japan.",
    "website": "http://www.emergency.co.jp",
    "zipcode": "112-0002"
  },
  "6090.T": {
    "city": "Tsuruoka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Human Metabolome Technologies, Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HUMAN METABOLOME TECHNOLOGIES I",
    "state": null,
    "summary": "Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is headquartered in Tsuruoka, Japan.",
    "website": "http://www.humanmetabolome.com",
    "zipcode": "997-0052"
  },
  "6095.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "MedPeer,Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDPEER INC",
    "state": null,
    "summary": "MedPeer,Inc. provides services for doctors in Japan. Its services include clinical and career support for doctors; marketing support for enterprises and advertisement/research business; and health promotion and prevention support business for general. The company operates and manages a doctor-owned community site under the MedPeer name. It also provides online health consultation services; doctor research services; and operates MedPeer career, a doctor-specialized recruiting information portal site. The company was founded in 2004 and is based in Tokyo, Japan.",
    "website": "http://medpeer.jp",
    "zipcode": "104-0061"
  },
  "6190.T": {
    "city": "Higashihiroshima",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "PhoenixBio Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHOENIXBIO CO LTD",
    "state": null,
    "summary": "PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments. Its contract study services in the field of drug discovery and development includes DMPK studies; safety studies; viral hepatitis-related studies; efficacy and safety studies for human specific nucleic acids, antibody, or polypeptide medicines; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.",
    "website": "http://www.phoenixbio.co.jp",
    "zipcode": "739-0046"
  },
  "6197.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Solasto Corporation",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SOLASTO CORPORATION",
    "state": null,
    "summary": "Solasto Corporation provides medical outsourcing services primarily to medical institutions in Japan. The company's medical outsourcing services include contracted services of medical clerical work. It also offers elderly care services, such as day service, home help, facility-based service, etc.; and childcare services, as well as engages in the education business. The company was formerly known as N.I.C Corporation. Solasto Corporation was founded in 1965 and is headquartered in Tokyo, Japan.",
    "website": "http://www.solasto.co.jp",
    "zipcode": "108-8210"
  },
  "6823.T": {
    "city": "Kokubunji",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Rion Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RION CO LTD",
    "state": null,
    "summary": "Rion Co., Ltd. manufactures, sells, and maintains hearing instruments, medical equipment, sound and vibration measuring instruments, particle counters, and related parts and equipment in Japan and internationally. The company's audiological equipment includes hearing instruments, such as analog and digital BTE, trimmer digital BTE, in-the-ear ready and custom made, and analog body aid instruments, as well as waterproof hearing instruments; and medical equipment comprising audiometers and OAE screeners. Its sound and vibration measuring instruments include sound level meters, vibration meters, seismometers, frequency analyzers, microphones and accelerometers, recorders, and other products. The company's particle counters comprise air and liquid- borne particle counters, and viable particle counters. Its products are primarily used in the applications of environment-related administration, electronics, semiconductors, pharmaceutical, and food manufacturing industries. The company was formerly known as Kobayashi-Riken Seisakusho Ltd. and changed its name to Rion Co., Ltd. in 1960. Rion Co., Ltd. was incorporated in 1944 and is headquartered in Kokubunji, Japan.",
    "website": "http://www.rion.co.jp",
    "zipcode": "185-8533"
  },
  "6849.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Nihon Kohden Corporation",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "NIHON KOHDEN CORP",
    "state": null,
    "summary": "Nihon Kohden Corporation develops, produces, and sells medical electronic equipment in Japan and internationally. It provides physiological measuring equipment, including electroencephalographs, electrocardiographs, evoked potential and electromyogram measuring systems, and polygraphs for cath labs, as well as diagnostic information systems and related consumables, such as recording papers, electrodes and catheters, and maintenance services. The company also offers patient monitors systems comprising central monitors, bedside monitors, wireless monitors, remote access software, and other equipment; and clinical information systems and related consumables and services, such as electrodes and sensors, and maintenance services. In addition, it provides treatment equipment, which include defibrillators, automated external defibrillators (AED), pacemakers, ventilators, anesthesia machines, cochlear implants, and related consumables and services, such as AED pads and batteries. Further, the company offers other medical equipment, including hematology analyzers, clinical chemistry analyzers, ultrasound diagnostic equipment, and equipment for research and others, as well as consumables, including test reagents, and installation and maintenance services. Nihon Kohden Corporation was founded in 1951 and is headquartered in Tokyo, Japan.",
    "website": "http://www.nihonkohden.com",
    "zipcode": "161-8560"
  },
  "6869.T": {
    "city": "Kobe",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Diagnostics & Research",
    "long_name": "Sysmex Corporation",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SYSMEX CORP",
    "state": null,
    "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
    "website": "http://www.sysmex.co.jp",
    "zipcode": "651-0073"
  },
  "6960.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Fukuda Denshi Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "FUKUDA DENSHI CO",
    "state": null,
    "summary": "Fukuda Denshi Co., Ltd. develops, manufactures, and sells medical electronic equipment worldwide. It provides resting electrocardiograph products; data management software; stress test products; Holter products and software; and patient monitoring systems, including central and bedside monitors, digital transmitters, and central viewer workstations. The company also offers defibrillator monitors; and ultrasound scanners, as well as vascular screening systems. Fukuda Denshi Co., Ltd. was founded in 1948 and is based in Tokyo, Japan.",
    "website": "http://www.fukuda.co.jp",
    "zipcode": "113-8420"
  },
  "6RC.F": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ReproCELL Incorporated",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "REPROCELL INC.",
    "state": null,
    "summary": "ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, and feeder cells; and 3D cell culture, labware, and drug discovery assays. The company also provides stem cell services, such as target cell isolation, iPSC reprogramming, and cell differentiation, as well as iPSC expansion, characterization, and banking services; and predictive drug discovery services in the areas of cardiac, vascular, respiratory, gastrointestinal, ADME/DMPK, skin/skin model, genitourinary, comparative pharmacology, and other assays. In addition, it offers human tissue samples, prospective collections, molecular, 3D cell, primary cell isolation, and DNA and RNA extraction services. ReproCELL Incorporated was founded in 2003 and is headquartered in Yokohama, Japan.",
    "website": "http://www.reprocell.com",
    "zipcode": "222-0033"
  },
  "6VX.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Healios K.K.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HEALIOS K.K.",
    "state": null,
    "summary": "Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.",
    "website": "http://www.healios.co.jp",
    "zipcode": "100-0006"
  },
  "7037.T": {
    "city": "Fukuoka City",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "teno. Holdings Company Limited",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TENO HOLDINGS CO LTD",
    "state": null,
    "summary": "teno. Holdings Company Limited provides public and consignment childcare services in Japan. The company provides public childcare services, such as operation of a nursery school and a childcare facility. It also offers contract childcare services, such as in-hospital/institutional childcare/company-led childcare; after-school childcare; and after school children's classroom promotion project, such as playground creation. In addition, the company offers home services, including babysitter, mothering, housework, staffing/dispatch, school (tenoschool), temporary childcare at the event, and nursing services. Holdings Company Limited was founded in 2015 and is headquartered in Fukuoka, Japan.",
    "website": "http://www.teno.co.jp",
    "zipcode": "812-0036"
  },
  "7061.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Japan Hospice Holdings Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "JAPAN HOSPICES HLDGS INC",
    "state": null,
    "summary": "Japan Hospice Holdings Inc. engages in hospice housing and home care businesses in Japan. The company offers care services at hospice housing for patients with terminal cancer and intractable diseases; and home-visit nursing services. It also provides home care services, which supports medical care, including physical care and life support, as well as offers day and nursing multi-function home care services. The company was founded in 2017 and is headquartered in Tokyo, Japan.",
    "website": "http://www.jhospice.co.jp",
    "zipcode": "100-0005"
  },
  "7071.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Amvis Holdings, Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "AMVIS HOLDINGS INC",
    "state": null,
    "summary": "Amvis Holdings, Inc. provides medical and nursing care services in Japan. It operates medical centers in Aomori, Iwate, Miyagi, Yamagata, Ibaraki, Tochigi, Saitama, Tokyo, Kanagawa, Niigata, Gifu, and Aichi. The company was founded in 2013 and is based in Tokyo, Japan.",
    "website": "http://www.amvis.co.jp",
    "zipcode": "103-0028"
  },
  "7079.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Health Information Services",
    "long_name": "WDB coco Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "WDB COCO CO LTD",
    "state": null,
    "summary": "WDB coco Co., Ltd. operates as a contracted drug development company. It supports the development of pharmaceuticals and medical devices with a focus on safety information management. The company was founded in 1984 and is headquartered in Tokyo, Japan.",
    "website": "http://www.wdbcoco.com",
    "zipcode": "104-6127"
  },
  "7090.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Ligua Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIGUA INC",
    "state": null,
    "summary": "Ligua Inc., a consultancy company, provides management support services in the healthcare industry. The company offers consulting services in the areas of sales office operations, such as sales improvement, organizational management, executive education, and recruitment; and corporate management areas comprising management of management figures and creation of business plans. It also provides problem solving tools for osteopaths; and insurance agency and financial products brokerage, and medical expenses billing agency services. Ligua Inc. was founded in 2004 and is headquartered in Osaka, Japan.",
    "website": "http://ligua.jp",
    "zipcode": "541-0047"
  },
  "7097.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Sakurasaku plus Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SAKURASAKU PLUS CO LTD",
    "state": null,
    "summary": "Sakurasaku plus Co.,Ltd. provides real estate brokerage and management services. It also operates child daycare centers. The company was founded in 2017 and is headquartered in Chiyoda, Japan.",
    "website": "http://www.sakurasakuplus.jp",
    "zipcode": "100-0006"
  },
  "71U.F": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Sawai Group Holdings Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SAWAI GROUP HOLDINGS CO.",
    "state": null,
    "summary": "Sawai Group Holdings Co., Ltd., together with subsidiaries, manufactures, sells, imports, and exports pharmaceutical products in Japan and the United States. The company offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. It serves hospitals, general practitioners, and dispensing pharmacies. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.",
    "website": "http://www.sawai.co.jp",
    "zipcode": "532-0003"
  },
  "7362.T": {
    "city": "Kyoto",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Terminalcare Support Institute Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TERMINALCARE SUPPORT INSTITUTE ",
    "state": null,
    "summary": "Terminalcare Support Institute Inc. provides home-visit long-term care, long-term care preventive home-visit, home care support, and serviced housing for the elderly. The company was founded in 2010 and is headquartered in Kyoto, Japan.",
    "website": "http://www.t-s-i.jp",
    "zipcode": "615-8074"
  },
  "7363.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "baby calendar Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BABY CALENDAR INC",
    "state": null,
    "summary": "baby calendar Inc. operates an information site for pregnancy, childbirth, and childcare in Japan. The company also operates a gift acceptance site; Moon Calendar, an information site that provides various information about menstruation; Woman Calendar, an anti-aging site for women by women; and long-term calendar, an information site that provides information for nursing care facilities for the elderly people. In addition, the company provides First gift card, a picture book with the pictures of the baby under the dacco brand name; and management support solutions in the areas of obstetrics and gynecology. Further, it offers touch panel monitors; and web marketing services. The company was formerly known as Cookpad Baby Co., Ltd. and changed its name to baby calendar Inc. in May 2017. baby calendar Inc. was founded in 1991 and is headquartered in Tokyo, Japan.",
    "website": "http://corp.baby-calendar.jp",
    "zipcode": "151-0053"
  },
  "7459.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "MediPal Holdings Corporation",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MEDIPAL HOLDINGS CORP",
    "state": null,
    "summary": "Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business. It also engages in delivering cosmetics, daily necessities, OTC pharmaceuticals, and other products; and animal health products and food processing raw materials wholesale business. In addition, it engages in the provision of cleaning management services; management and operation of distribution centers; planning, management, administration, and product and service development for the Class A dispensing pharmacy service brand; management and marketing support for dispensing pharmacies; and import/export wholesale distribution. Further, it offers health insurance claims review, medical coding dispatch, outsourcing, and remote education services; non-life insurance agency services; medical supply and master product databases for medical facilities; and commissioned delivery and worker dispatch services. The company serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. Medipal Holdings Corporation was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. The company was founded in 1898 and is headquartered in Tokyo, Japan.",
    "website": "http://www.medipal.co.jp",
    "zipcode": "104-8461"
  },
  "7575.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Japan Lifeline Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "JAPAN LIFELINE CO",
    "state": null,
    "summary": "Japan Lifeline Co., Ltd., a medical device company, develops, produces, imports, distributes, and trades in cardiovascular related medical devices in Japan. Its cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, and automated external defibrillators; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, and radio-frequency transseptal needles. The company's cardiovascular and vascular surgery products consist of vascular and open stent grafts, and abdominal stent-grafts; and transvascular intervention products include PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and atrial septal defect closure devices. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.",
    "website": "http://www.japanlifeline.com",
    "zipcode": "140-0002"
  },
  "7634.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "Hoshi Iryo-Sanki Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HOSHIIRYO-SANKI CO LTD",
    "state": null,
    "summary": "Hoshi Iryo-Sanki Co., Ltd. manufactures and sells pharmaceutical medical oxygen and nitrous oxides in Japan. It also plans, manufactures, sells, maintains, inspects, and repairs medical instruments equipment for medical gas supply facilities, and care and welfare equipment, as well as provides home oxygen therapy support services. In addition, the company operates nursing homes and day care facilities. Hoshi Iryo-Sanki Co., Ltd. was founded in 1960 and is headquartered in Tokyo, Japan.",
    "website": "http://www.hosi.co.jp",
    "zipcode": "121-0836"
  },
  "7649.T": {
    "city": "Obu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Sugi Holdings Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUGI HOLDINGS CO.LTD.",
    "state": null,
    "summary": "Sugi Holdings Co.,Ltd. operates drugstores in Japan. It also provides visiting nursing services and home care support services. As of June 1, 2019, the company operated 1,190 stores. Sugi Holdings Co.,Ltd. was founded in 1976 and is headquartered in Obu, Japan.",
    "website": "http://www.drug-sugi.co.jp/hd/index.html",
    "zipcode": "474-0011"
  },
  "7679.T": {
    "city": "Shiwa",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "YAKUODO HOLDINGS Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "YAKUODO HLDGS CO LTD",
    "state": null,
    "summary": "YAKUODO HOLDINGS Co., Ltd., through its subsidiaries, engages in the management of drug stores and dispensing pharmacies in Japan. It operates 297 stores. The company was founded in 1978 and is headquartered in Shiwa, Japan.",
    "website": "http://www.yakuodo-hd.co.jp",
    "zipcode": "028-3621"
  },
  "7681.T": {
    "city": "Settsu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "LEOCLAN Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LEOCLAN CO LTD",
    "state": null,
    "summary": "LEOCLAN Co.,Ltd. operates as a medical equipment trading company that meets various medical, welfare, and health needs. It provides consulting, information consulting, medical equipment and device information, and healthcare services, as well as proposes medical equipment to design offices and construction companies. The company was founded in 2001 and is headquartered in Settsu, Japan.",
    "website": "http://www.leoclan.co.jp",
    "zipcode": "566-0001"
  },
  "7688.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "Miahelsa Corporation",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MIAHELSA CORP",
    "state": null,
    "summary": "Miahelsa Corporation engages in pharmaceutical, nursing care, childcare, and food businesses in Japan. The company operates dispensing pharmacies and nursery schools; and sells food ingredients. It operates 41 dispensing pharmacies; and 21 nursery schools, 1 certified nursery school, and 1 hospital nursery school. The company was founded in 1984 and is headquartered in Tokyo, Japan.",
    "website": "http://www.merhalsa.jp",
    "zipcode": "162-0054"
  },
  "7716.T": {
    "city": "Kanuma",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nakanishi Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NAKANISHI INC",
    "state": null,
    "summary": "Nakanishi Inc. manufactures and sells dental, industrial, and medical products worldwide. The company offers turbines; clinical micromotors; contra-angles; and built-in, mobile dentistry, oral hygiene, endodontic, surgical, dental laboratory, and hygiene and maintenance products. It also offers motor spindles, and micro gridlers and tools. The company serves automotive, micromechanics, electronics, medical, die/mold, aerospace, and energy industries. Nakanishi Inc. was founded in 1930 and is headquartered in Kanuma, Japan.",
    "website": "http://www.nsk-nakanishi.co.jp/industrial-eng",
    "zipcode": "322-8666"
  },
  "7733.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Olympus Corporation",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OLYMPUS CORPORATION",
    "state": null,
    "summary": "Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through five segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, Imaging Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, video and other endoscopes system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Imaging Business segment provides digital cameras, IC and voice recorders, mirrorless interchangeable-lens cameras, and interchangeable lenses. The Others segment offers biomedical materials. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and GI- and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.",
    "website": "http://www.olympus-global.com",
    "zipcode": "163-0914"
  },
  "7741.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "HOYA Corporation",
    "market": "jp_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "HOYA CORP",
    "state": null,
    "summary": "HOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company operates through three segments: Life Care, Information Technology, and Other. The Life Care segment offers healthcare products, including eyeglass and contact lenses; and medical products, such as medical endoscopes, laparoscopic surgical instruments, intraocular lenses, and prosthetic ceramic fillers and orthopedic implants. This segment also operates ÂEyecity', a chain of specialist contact lens stores. The Information Technology segment provides electronics products comprising mask blanks and photomasks for manufacturing semiconductor chips; photomasks for liquid crystal display panels; and glass disks for hard disk drives. This segment also offers imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. The Other segment provides various IT solutions, which comprise system architecture and information processing, business application software, ERP solutions, and internet services; speech synthesis software; and cloud services. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.",
    "website": "http://www.hoya.co.jp",
    "zipcode": "160-8347"
  },
  "7747.T": {
    "city": "Aichi",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Asahi Intecc Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ASAHI INTECC CO LTD",
    "state": null,
    "summary": "Asahi Intecc Co., Ltd. develops, manufactures, and sells medical devices in Japan and internationally. The company provides percutaneous transluminal coronary angioplasty (PTCA) guide wires, PTCA guiding catheters, PTCA balloon catheters, and penetration catheters for cardiology; peripheral guide wires, IVR guide wires, micro catheters, and cerebrovascular system guide wires for peripheral vascular, abdominal vascular, and cerebrovascular systems; and guide wires and catheters for angiography. It also offers OEM services for medical devices; and medical and industrial components, such as element wires, stranded conductors, coils, tubes, terminal processing products, and other products, as well as ultra-fine stainless steel wire ropes, terminal processed products, etc. Asahi Intecc Co., Ltd. has business alliance agreement with Oncolys BioPharma. The company was formerly known as Asahi Mini Rope Sales Co., Ltd. and changed its name to Asahi Intecc Co., Ltd. in July 1988. Asahi Intecc Co., Ltd. was founded in 1976 and is headquartered in Aichi, Japan.",
    "website": "http://www.asahi-intecc.co.jp",
    "zipcode": "489-0071"
  },
  "7749.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Medikit Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDIKIT CO LTD",
    "state": null,
    "summary": "Medikit Co.,Ltd. engages in the manufacture and sale of vascular access medical devices. The company offers IV catheters, such as supercath 5, supercath Z3V, and supercath Ztu-V for hospitals and emergency services; hemodialysis products, including supercath NEO and supercath CLS; and intervention products comprising Supersheath, Mongoose, and Meito Masamune. Its products are used in anesthetic departments, operating theaters, ICUs, and dialysis and cardiology units. The company markets its products through distributors in approximately 20 countries and territories in the European Union and on the American continent. Medikit Co.,Ltd. was founded in 1973 and is headquartered in Tokyo, Japan.",
    "website": "http://www.medikit.co.jp",
    "zipcode": "113-0034"
  },
  "7774.T": {
    "city": "Gamagori",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "Japan Tissue Engineering Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "JAPAN TISSUE ENGINEERING CO LTD",
    "state": null,
    "summary": "Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company offers autologous cultured epidermis and cartilage to medical institutions for the purpose of medical treatment. It also provides tissue-engineered medical products, which are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured, and then transplanted back to the same patient. In addition, the company researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, it offers regenerative medical products contract development and manufacturing, and contract research services. Japan Tissue Engineering Co., Ltd. was founded in 1999 and is headquartered in Gamagori, As of March 2, 2021, Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.",
    "website": "http://www.jpte.co.jp",
    "zipcode": "443-0022"
  },
  "7775.T": {
    "city": "Izumi",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Daiken Medical Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DAIKEN MEDICAL CO LTD",
    "state": null,
    "summary": "Daiken Medical Co., Ltd. manufactures and distributes medical devices and equipment in Japan and internationally. The company's products include syringe pumps, disposable infusion pumps, portable disposable infusors, endobronchinal blocker tubes, suction containers, connecting tubes, suction tips, medical hand washing machines, disposable medical towels, and sterilize mats. It also trades in medical equipment. The company sells its products under the COOPDECH brand name. Daiken Medical Co., Ltd. was incorporated in 1968 and is headquartered in Izumi, Japan.",
    "website": "http://www.daiken-iki.co.jp",
    "zipcode": "594-1157"
  },
  "7776.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Biotechnology",
    "long_name": "CellSeed Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CELLSEED INC",
    "state": null,
    "summary": "CellSeed Inc. develops regenerative medicine products primarily in Japan and internationally. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides contract development and manufacturing services. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
    "website": "http://www.cellseed.com",
    "zipcode": "135-0064"
  },
  "7779.T": {
    "city": "Tsukuba",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "CYBERDYNE Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CYBERDYNE INC",
    "state": null,
    "summary": "CYBERDYNE Inc. manufactures and sells medical devices in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use for people who have disorders in the lower limb and leg weaknesses, as well as non-medical HAL; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides HAL Therapy, a medical service to provide medical treatment for functional improvement of patients with cerebral, nervous, spinal cord injury, and cerebral embolism disorders; and non-medical services, such as HAL FIT and ROBO CARE training programs. The company operates 16 Neuro HALFIT service centers. CYBERDYNE Inc. has a strategic partnership with CellSource Co., Ltd. to jointly discover new treatment methods for patients with osteoarthritis of the knee caused by aging. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.",
    "website": "http://www.cyberdyne.jp",
    "zipcode": "305-0818"
  },
  "7780.T": {
    "city": "Nagoya",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Menicon Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MENICON CO LTD",
    "state": null,
    "summary": "Menicon Co., Ltd. manufactures and sells contact lenses and lens care products worldwide. It provides soft, GP, and specialty lenses. The company was incorporated in 1943 and is headquartered in Nagoya, Japan",
    "website": "http://www.menicon.co.jp",
    "zipcode": "460-0006"
  },
  "7782.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sincere Co., LTD.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SINCERE CO LTD",
    "state": null,
    "summary": "Sincere Co., LTD. manufactures and sells contact lens in Japan. The company was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.sincere-vision.com",
    "zipcode": "113-0033"
  },
  "7813.T": {
    "city": "Onojo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Platz Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PLATZ CO LTD",
    "state": null,
    "summary": "Platz Co., Ltd. produces and sells care beds, mattresses, and other add-on equipment in Japan. The company's products include nursing care beds, hospital beds, care facility beds, reclining beds, mattress, and accessories, such as bed grip, side rail, table, floor protection carpet pads, and other related products. It serves retailers of medical devices and nursing care goods, as well as furniture shops. The company was formerly known as Kyushu Waken ltd. and changed its name to Platz Co., Ltd. in June 1995. Platz Co., Ltd. was founded in 1992 and is based in Onojo, Japan.",
    "website": "http://www.platz-ltd.co.jp",
    "zipcode": "816-0921"
  },
  "7817.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Paramount Bed Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PARAMOUNT BED HOLDINGS CO LTD",
    "state": null,
    "summary": "Paramount Bed Holdings Co., Ltd. manufactures and sells hospital beds worldwide. The company offers mattresses and equipment for medical and nursing care environments; and home care products. It is also involved in the inspection and maintenance of Paramount bed products; and the leasing and wholesale of welfare care products. Paramount Bed Holdings Co., Ltd. was founded in 1947 and is headquartered in Tokyo, Japan.",
    "website": "http://www.paramount.co.jp",
    "zipcode": "136-8671"
  },
  "7963.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Devices",
    "long_name": "Koken Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KOKEN LTD",
    "state": null,
    "summary": "Koken Ltd., together with its subsidiaries, produces and sells occupational personal protective equipment in Japan and internationally. It operates in Mask-Related Business and Other Businesses segments. The company offers clean air solutions, including KOACH, an open clean zone creator; KOKENLAMINAR, a push-pull ventilation system; and LAMIKOACH, an air ventilation system as contamination source control. It also provides IMADEZE, a copper-based lactate antibacterial agent; masks for medical facilities and general consumers; and functional water production systems, such as electrolyzed water generators, endoscope washers/disinfectors, blood stain washer kits, and portable showers, as well as magnetic water treatment systems. In addition, the company offers respirators for industrial use, including particulate respirators, powered air-purifying respirators, supplied air respirators, chemical cartridge respirators, and gas masks; respirators for general consumers; equipment for accident and disaster countermeasures; and protective clothes, ear plugs, face shields, etc. Koken Ltd. was founded in 1943 and is headquartered in Tokyo, Japan.",
    "website": "http://www.koken-ltd.co.jp",
    "zipcode": null
  },
  "7979.T": {
    "city": "Kyoto",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Shofu Inc.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SHOFU INC",
    "state": null,
    "summary": "Shofu Inc. manufactures and sells dental materials and equipment worldwide. Its products include artificial teeth, dental porcelains, dental abrasives and polishers, dental alloys, dental cements, restorative materials, dental waxes, dental investments/stones, orthodontic devices, and preventive infection control goods. The company was formerly known as Shofu Dental Mfg. Co., Ltd. and changed its name to Shofu Inc. in 1983. Shofu Inc. was founded in 1922 and is based in Kyoto, Japan.",
    "website": "http://www.shofu.co.jp",
    "zipcode": "605-0983"
  },
  "8086.T": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nipro Corporation",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NIPRO CORP",
    "state": null,
    "summary": "Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations. The company's Pharma Packaging business offers glass vials, ampoules, syringes, and cartridges; glass tubes; glass forming machinery; glass bulbs for vacuum flasks; and other parts of pharmaceutical packaging, such as rubber plugs. Its Other business provides thermostable enzymes for clinical chemistry. The company also offers business management services. Nipro Corporation serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.",
    "website": "http://www.nipro.co.jp",
    "zipcode": "531-8510"
  },
  "8095.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Astena Holdings Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ASTENA HOLDINGS CO LTD",
    "state": null,
    "summary": "Astena Holdings Co.,Ltd. manufactures and sells medicine-related products in Japan. The company's Fine Chemical division manufactures and sells active pharmaceutical ingredients and medical supplies for antipyretic, analgesic, anti-inflammatory, and vasoconstrictor areas. Its Medical division is involved in the biotechnology related business, such as the provision of drug development support services; and sale of medical equipment. The company's Health & Beauty Care, and Food division engages in the sale of over-the-counter drugs, food product materials, functional food product materials, and cosmetic ingredients; mail/Internet-ordered sales business; and OEM production of cosmetics. Its Industrial Chemicals division manufactures and sells surface finishing chemicals and other chemical products, such as products for PWBs, electronic devices, general platings, and semiconductors. The company was formerly known as Iwaki & Co., Ltd. and changed its name to Astena Holdings Co.,Ltd. in June 2021. Astena Holdings Co.,Ltd. was founded in 1914 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astena-hd.com",
    "zipcode": "103-8403"
  },
  "8C4.F": {
    "city": "Tsukuba",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "CYBERDYNE Inc.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CYBERDYNE INC.",
    "state": null,
    "summary": "CYBERDYNE Inc. manufactures and sells medical devices in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use for people who have disorders in the lower limb and leg weaknesses, as well as non-medical HAL; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides HAL Therapy, a medical service to provide medical treatment for functional improvement of patients with cerebral, nervous, spinal cord injury, and cerebral embolism disorders; and non-medical services, such as HAL FIT and ROBO CARE training programs. The company operates 16 Neuro HALFIT service centers. CYBERDYNE Inc. has a strategic partnership with CellSource Co., Ltd. to jointly discover new treatment methods for patients with osteoarthritis of the knee caused by aging. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.",
    "website": "http://www.cyberdyne.jp",
    "zipcode": "305-0818"
  },
  "9265.T": {
    "city": "Fukuoka",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "Yamashita Health Care Holdings,Inc.",
    "market": "jp_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "YAMASHITA HEALTH CARE HOLDINGS ",
    "state": null,
    "summary": "Yamashita Health Care Holdings,Inc. engages in the wholesale of medical equipment in Japan. The company is also involved in the medical IT business; and design, construction, and maintenance of equipment. In addition, it offers management consulting support and consumables management logistics services; and manufactures and sells medical instruments and orthopedic implants. The company is based in Fukuoka, Japan.",
    "website": "http://www.yhchd.co.jp",
    "zipcode": "810-0004"
  },
  "9267.T": {
    "city": "Sakai",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Genky DrugStores Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GENKY DRUGSTORES CO LTD",
    "state": null,
    "summary": "Genky DrugStores Co., Ltd. operates a chain of drug stores in Japan. The company was founded in 1988 and is headquartered in Sakai, Japan.",
    "website": "http://www.genkydrugstores.co.jp",
    "zipcode": "910-0332"
  },
  "9273.T": {
    "city": "Yokohama",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Koa Shoji Holdings Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KOA SHOJI HOLDINGS CO LTD",
    "state": null,
    "summary": "Koa Shoji Holdings Co.,Ltd., through its subsidiaries, engages in import and sale of generic APIs/intermediates in Japan. It is also involved in the manufacture of various injections; OTC drugs, primarily various vitamins; and generic drugs. In addition, the company engages in contract manufacturing of pharmaceuticals; and packaging of pharmaceutical products. Koa Shoji Holdings Co.,Ltd. was founded in 1991 and is headquartered in Yokohama, Japan.",
    "website": "http://www.koashoji-hd.com",
    "zipcode": "223-0061"
  },
  "9707.T": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Care Facilities",
    "long_name": "UNIMAT Retirement Community Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "UNIMAT SOYOKAZE CO. LTD.",
    "state": null,
    "summary": "UNIMAT Retirement Community Co., Ltd. engages in the nursing care and retirement community businesses in Japan. The company offers nursing care services, such as day service, short stay, home-visit nursing care, home with nursing care, and housing for the elderly with services; meal delivery services; life planning services; recruiting services; and senior service consulting services. It also operates Hotel Allamanda Aoyama in Aoyama, Tokyo; and Allamanda Spa Aoyama Club, as well as restaurants, cafes, spas, fitness, and housing for seniors. In addition, the company processes and sells coffee beans; and developing services for enhancing long-term care operations, and maintains and improves the health of seniors utilizing big data, AI, sensors, etc. The company was formerly known as Unimat Soyokaze Co., Ltd. and changed its name to UNIMAT Retirement Community Co., Ltd. in October 2015. UNIMAT Retirement Community Co., Ltd. was founded in 1974 and is headquartered in Tokyo, Japan.",
    "website": "http://www.unimat-rc.co.jp",
    "zipcode": "107-0061"
  },
  "9776.T": {
    "city": "Sapporo",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Sapporo Clinical Laboratory Inc.",
    "market": "jp_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SAPPORO CLINICAL LABORATORIES",
    "state": null,
    "summary": "Sapporo Clinical Laboratory Inc. operates dispensing pharmacies in Japan. The company offers laboratory testing, pathological examination, and holter inspection services. It also provides food hygiene environmental inspection, including food/processed product, facility hygiene, and food handler inspection services; and radiation management services. In addition, the company develops, sells, and maintains software, such as SCAN clinical testing systems; and offers support services for opening new clinics. Further, it provides HiWeb21 inspection result inquiry services. Sapporo Clinical Laboratory Inc. was founded in 1965 and is headquartered in Sapporo, Japan.",
    "website": "http://www.saturin.co.jp",
    "zipcode": "060-0005"
  },
  "9987.T": {
    "city": "Nagoya",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Medical Distribution",
    "long_name": "Suzuken Co., Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUZUKEN CO LTD",
    "state": null,
    "summary": "Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates through four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business segments. The Pharmaceutical Distribution Business segment engages in the procurement and supply of ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research, development, manufacturing, and marketing of pharmaceuticals, as well as diagnostic products focusing on diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as enhances the operations of local pharmacies through training and education. The Healthcare-Related Services Business segment provides manufacturer support services in the form of contract distribution for manufacturers and orphan drugs; and nursing care services, as well as engages in the manufacturing of electrocardiographs, sphygmomanometers, and other medical equipment. The company also publishes medical magazines for medical institutions. Suzuken Co., Ltd. has collaboration with Bushu Pharmaceuticals Ltd. for specialty pharmaceuticals. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.",
    "website": "http://www.suzuken.co.jp",
    "zipcode": "461-8701"
  },
  "9989.T": {
    "city": "Fuchu",
    "country": "Japan",
    "currency": "JPY",
    "exchange": "JPX",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Sundrug Co.,Ltd.",
    "market": "jp_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUNDRUG CO LTD",
    "state": null,
    "summary": "Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offers food, cosmetics, home appliances, clothing, car supplies, sports and goods, alcoholic beverages, and pharmaceutical products, as well as fresh food, kerosene, etc. The company was founded in 1957 and is headquartered in Fuchu, Japan.",
    "website": "http://www.sundrug.co.jp",
    "zipcode": "183-0005"
  },
  "9SO.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Solasia Pharma K.K.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SOLASIA PHARMA K.K.  O.N.",
    "state": null,
    "summary": "Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 (PledOx), an intracellular superoxide removing agent, which is in phase IIb clinical trials for chemotherapy induced peripheral neuropathy. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.",
    "website": "http://www.solasia.co.jp",
    "zipcode": "105-0011"
  },
  "9UN.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "MedPeer,Inc.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDPEER INC.",
    "state": null,
    "summary": "MedPeer,Inc. provides services for doctors in Japan. Its services include clinical and career support for doctors; marketing support for enterprises and advertisement/research business; and health promotion and prevention support business for general. The company operates and manages a doctor-owned community site under the MedPeer name. It also provides online health consultation services; doctor research services; and operates MedPeer career, a doctor-specialized recruiting information portal site. The company was founded in 2004 and is based in Tokyo, Japan.",
    "website": "http://medpeer.jp",
    "zipcode": "104-0061"
  },
  "AJW.F": {
    "city": "Ibaraki",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "AnGes, Inc.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ANGES, INC.",
    "state": null,
    "summary": "AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.",
    "website": "http://www.anges.co.jp",
    "zipcode": "567-0085"
  },
  "ALPMF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "ALPMY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "BMZ.MU": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Diagnostics & Research",
    "long_name": "BML, Inc.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BML INC.",
    "state": null,
    "summary": "BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis; microbiological tests for medical and pharmaceutical societies and organizations; and laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies. It also develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, and subsequent test procedures; and provides electronic medical charts for networking medical information, as well as offers preventive medicine services. In addition, the company provides food sanitation control and food processing services comprising contract services for microorganism testing of raw materials, and prepared and processed foods; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and waste water tests; work sanitation management services, such as measurement of ethylene oxide gas, formaldehyde, organic solvents, and dust; environmental monitoring services, including measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal diseases; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. BML, Inc. was founded in 1955 and is headquartered in Tokyo, Japan.",
    "website": "http://www.bml.co.jp",
    "zipcode": null
  },
  "CHGCF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "CHGCY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "CUP.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Chugai Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CHUGAI PHARMACEUT'L",
    "state": null,
    "summary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.",
    "website": "http://www.chugai-pharm.co.jp",
    "zipcode": "103-8324"
  },
  "CYBQF": {
    "city": "Tsukuba",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "CYBERDYNE Inc.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CYBERDYNE INC",
    "state": null,
    "summary": "CYBERDYNE Inc. manufactures and sells medical devices in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use for people who have disorders in the lower limb and leg weaknesses, as well as non-medical HAL; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides HAL Therapy, a medical service to provide medical treatment for functional improvement of patients with cerebral, nervous, spinal cord injury, and cerebral embolism disorders; and non-medical services, such as HAL FIT and ROBO CARE training programs. The company operates 16 Neuro HALFIT service centers. CYBERDYNE Inc. has a strategic partnership with CellSource Co., Ltd. to jointly discover new treatment methods for patients with osteoarthritis of the knee caused by aging. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.",
    "website": "http://www.cyberdyne.jp",
    "zipcode": "305-0818"
  },
  "CYBQY": {
    "city": "Tsukuba",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "CYBERDYNE Inc.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CYBERDYNE INC",
    "state": null,
    "summary": "CYBERDYNE Inc. manufactures and sells medical devices in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use for people who have disorders in the lower limb and leg weaknesses, as well as non-medical HAL; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides HAL Therapy, a medical service to provide medical treatment for functional improvement of patients with cerebral, nervous, spinal cord injury, and cerebral embolism disorders; and non-medical services, such as HAL FIT and ROBO CARE training programs. The company operates 16 Neuro HALFIT service centers. CYBERDYNE Inc. has a strategic partnership with CellSource Co., Ltd. to jointly discover new treatment methods for patients with osteoarthritis of the knee caused by aging. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.",
    "website": "http://www.cyberdyne.jp",
    "zipcode": "305-0818"
  },
  "D4S.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO CO. LTD",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "DMTRF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "3-D Matrix, Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "3-D MATRIX LTD",
    "state": null,
    "summary": "3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was founded in 2004 and is based in Tokyo, Japan.",
    "website": "http://www.3d-matrix.co.jp",
    "zipcode": "102-0083"
  },
  "DNPUF": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Sumitomo Dainippon Pharma Co., Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUMITOMO DAINIPPON PHARMA CO LT",
    "state": null,
    "summary": "Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.",
    "website": "http://www.ds-pharma.com",
    "zipcode": "541-0045"
  },
  "DPA.F": {
    "city": "Toyama",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Daito Pharmaceutical Co.,Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DAITO PHARMACEUTICAL",
    "state": null,
    "summary": "Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was founded in 1942 and is headquartered in Toyama, Japan.",
    "website": "http://www.daitonet.co.jp",
    "zipcode": "939-8567"
  },
  "DPM.F": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Sumitomo Dainippon Pharma Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUMITOMO DAINIPPON PHARMA",
    "state": null,
    "summary": "Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.",
    "website": "http://www.ds-pharma.com",
    "zipcode": "541-0045"
  },
  "DSKYF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO COMPANY LIMITED",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "DSNKY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Daiichi Sankyo Company, Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "DAIICHI SANKYO COMPANY LIMITED",
    "state": null,
    "summary": "Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.",
    "website": "http://www.daiichisankyo.com",
    "zipcode": "103-8426"
  },
  "EII.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Eisai Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "EISAI CO. LTD",
    "state": null,
    "summary": "Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.",
    "website": "http://www.eisai.co.jp",
    "zipcode": "112-8088"
  },
  "EMO.F": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "EM Systems Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "EM HOLDINGS CO.",
    "state": null,
    "summary": "EM Systems Co., Ltd. develops and sells various IT systems for pharmacies, clinics, and care/welfares in Japan. It also develops and sells IT systems for pharmacies, such as medical fee receipt computers and electronic medication record systems; IT systems for clinics, including medical accounting and electronic medical record systems; and office processing systems for care/welfare providers. The company was founded in 1980 and is headquartered in Osaka, Japan.",
    "website": "http://www.emsystems.co.jp",
    "zipcode": "532-0003"
  },
  "EPLYF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "EPS Holdings, Inc.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "EPS HOLDINGS INC",
    "state": null,
    "summary": "EPS Holdings, Inc., through its subsidiaries, provides outsourced solutions to customers in the healthcare industry. It provides contract research organization (CRO) services and management of CRO segment activities; site management organization services; contract MR services, DI, and other call center services related BPO services, as well as medical device support services; contract sales solutions, including recruitment, training, and development of MRs (permanent, contract staffing, and temp to-perm), as well as medical communications programs and training; and promotion and BPO services for healthcare companies. The company also engages in clinical research related business; provision of IT services for pharmaceutical and medical settings; the import and export of products for non-clinical research, and provision of distribution services; research and development, manufacture, and sale of pharmaceuticals and medical devices; and provision of human studies (functionality and safety evaluations), basic research and animal studies, food composition analysis, research on functional substances, and other research and analysis services, as well as consulting in support of functional food development and other activities. In addition, it engages in trading, investment, and other businesses; shared services; rental and sale of advanced medical and other devices; and sale of clinical trial and other types of life and non-life insurance. The company serves pharmaceutical companies, medical device manufacturers, pharmaceutical development ventures, medical institutions, and universities and research institution in Japan and Asia. EPS Holdings, Inc. was founded in 1991 and is based in Tokyo, Japan.",
    "website": "http://www.eps-holdings.co.jp",
    "zipcode": "162-0821"
  },
  "ESALY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Eisai Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "EISAI CO",
    "state": null,
    "summary": "Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.",
    "website": "http://www.eisai.co.jp",
    "zipcode": "112-8088"
  },
  "FUP.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Fuji Pharma Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "FUJI PHARMA CO.LTD.",
    "state": null,
    "summary": "Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers hormone medicines for obstetrics and gynecology therapies, as well as injectable drugs, such as radiopharmaceutical products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. The company was founded in 1965 and is headquartered in Tokyo, Japan.",
    "website": "http://www.fujipharma.jp",
    "zipcode": "102-0075"
  },
  "HLOSF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Healios K.K.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HEALIOS KK",
    "state": null,
    "summary": "Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.",
    "website": "http://www.healios.co.jp",
    "zipcode": "100-0006"
  },
  "HOCPF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "HOYA Corporation",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "HOYA CORP",
    "state": null,
    "summary": "HOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company operates through three segments: Life Care, Information Technology, and Other. The Life Care segment offers healthcare products, including eyeglass and contact lenses; and medical products, such as medical endoscopes, laparoscopic surgical instruments, intraocular lenses, and prosthetic ceramic fillers and orthopedic implants. This segment also operates ÂEyecity', a chain of specialist contact lens stores. The Information Technology segment provides electronics products comprising mask blanks and photomasks for manufacturing semiconductor chips; photomasks for liquid crystal display panels; and glass disks for hard disk drives. This segment also offers imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. The Other segment provides various IT solutions, which comprise system architecture and information processing, business application software, ERP solutions, and internet services; speech synthesis software; and cloud services. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.",
    "website": "http://www.hoya.co.jp",
    "zipcode": "160-8347"
  },
  "HOCPY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "HOYA Corporation",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "HOYA CORP",
    "state": null,
    "summary": "HOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company operates through three segments: Life Care, Information Technology, and Other. The Life Care segment offers healthcare products, including eyeglass and contact lenses; and medical products, such as medical endoscopes, laparoscopic surgical instruments, intraocular lenses, and prosthetic ceramic fillers and orthopedic implants. This segment also operates ÂEyecity', a chain of specialist contact lens stores. The Information Technology segment provides electronics products comprising mask blanks and photomasks for manufacturing semiconductor chips; photomasks for liquid crystal display panels; and glass disks for hard disk drives. This segment also offers imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. The Other segment provides various IT solutions, which comprise system architecture and information processing, business application software, ERP solutions, and internet services; speech synthesis software; and cloud services. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.",
    "website": "http://www.hoya.co.jp",
    "zipcode": "160-8347"
  },
  "HPX.F": {
    "city": "Tosu",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Hisamitsu Pharmaceutical Co., Inc.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "HISAMITSU PHARMA.",
    "state": null,
    "summary": "Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan. The company provides analgesic / anti-inflammatory patches; athlete's foot / ringworm remedy products; allergy-only rhinitis drugs; eye drops; high cholesterol improving drugs; acne remedies; cooling sheets; and supporters for knee, waist, elbow, calf and ankle. It also provides cooling sprays; bactericidal antibacterial spray and deodorant spray; ship fixing sheet; adhesive plasters for magnetic products; skin care products; sweat sheet; massage roller gel and oil spray; thermal equipment, and dietary supplements. The company offers its products under the Salon pass, Salonship, Air Salon Pass, Fatus, Butena Rock, Allegra, Direct pasting, Choleston, Life Cera, Deco Deco Cool, Children Robin Eye Plus. Eye cool, MSM, and other brand names. It sells its products in North America, Central and South America, Asia, Oceania, the Middle East, Africa, and Europe. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.",
    "website": "http://www.hisamitsu.co.jp",
    "zipcode": "841-0017"
  },
  "HTSUF": {
    "city": "Tosu",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Hisamitsu Pharmaceutical Co., Inc.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "HISAMITSU PHARMACEUTICAL CO INC",
    "state": null,
    "summary": "Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan. The company provides analgesic / anti-inflammatory patches; athlete's foot / ringworm remedy products; allergy-only rhinitis drugs; eye drops; high cholesterol improving drugs; acne remedies; cooling sheets; and supporters for knee, waist, elbow, calf and ankle. It also provides cooling sprays; bactericidal antibacterial spray and deodorant spray; ship fixing sheet; adhesive plasters for magnetic products; skin care products; sweat sheet; massage roller gel and oil spray; thermal equipment, and dietary supplements. The company offers its products under the Salon pass, Salonship, Air Salon Pass, Fatus, Butena Rock, Allegra, Direct pasting, Choleston, Life Cera, Deco Deco Cool, Children Robin Eye Plus. Eye cool, MSM, and other brand names. It sells its products in North America, Central and South America, Asia, Oceania, the Middle East, Africa, and Europe. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.",
    "website": "http://www.hisamitsu.co.jp",
    "zipcode": "841-0017"
  },
  "HYB.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "HOYA Corporation",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "HOYA CORP.",
    "state": null,
    "summary": "HOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company operates through three segments: Life Care, Information Technology, and Other. The Life Care segment offers healthcare products, including eyeglass and contact lenses; and medical products, such as medical endoscopes, laparoscopic surgical instruments, intraocular lenses, and prosthetic ceramic fillers and orthopedic implants. This segment also operates ÂEyecity', a chain of specialist contact lens stores. The Information Technology segment provides electronics products comprising mask blanks and photomasks for manufacturing semiconductor chips; photomasks for liquid crystal display panels; and glass disks for hard disk drives. This segment also offers imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. The Other segment provides various IT solutions, which comprise system architecture and information processing, business application software, ERP solutions, and internet services; speech synthesis software; and cloud services. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.",
    "website": "http://www.hoya.co.jp",
    "zipcode": "160-8347"
  },
  "JMD.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Japan Medical Dynamic Marketing, INC.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "JP.MEDICAL DY.MARK.",
    "state": null,
    "summary": "Japan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan. It provides trauma devices, including nails, screws, plates, and other products surgically implanted in the fracture site; joint prostheses, which replaces natural joints and restores functions damaged or lost due to disease or injury; spinal fixation devices for the use in spinal instability surgery; and artificial bone fillers for the treatment of bone fractures, tumors, and other defects. The company offers its products to medical professionals and hospitals. The company was founded in 1973 and is headquartered in Tokyo, Japan.",
    "website": "http://www.jmdm.co.jp",
    "zipcode": "162-0066"
  },
  "JSS.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Sosei Group Corporation",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SOSEI GROUP CORP",
    "state": null,
    "summary": "Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of tumors and metastatic castration resistant prostate cancer; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage to treat migraine and other severe headaches; PF-07081532 and PF-07054894, which are in Phase l for use in multiple therapeutic areas; HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial to treat neurological order; GPR35 agonist to treat inflammatory bowel disease; and KY1051, which is in preclinical stage for the treatment of immuno-oncology. It also offers HTL0016878, a muscarinic M4 receptor agonist, which is in Phase I clinical trial for the treatment of Alzheimer's disease; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial to treat endocrine disorders; GLP-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; H4 antagonist, which is in preclinical stage to treat atopic dermatitis; EP4 antagonist, which is in preclinical stage to mediate PGE2 immunosuppression; GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage to treat intestinal disorder; GPR52 agonist to treat of neurology disease; and PAR2 mAb for the treatment of atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab; PeptiDream Inc; Pfizer; AbbVie; Biohaven; GSK; AstraZeneca; Novartis; Genentech; Takeda Pharmaceutical Company Limited; and Metrion Biosciences Limited. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.",
    "website": "http://soseiheptares.com",
    "zipcode": "102-0083"
  },
  "KA3.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "KAINOS Laboratories, Inc.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KAINOS LABORATORIES",
    "state": null,
    "summary": "KAINOS Laboratories, Inc. develops, manufactures, markets, distributes, and imports/exports pharmaceuticals, diagnostic reagents, related chemical products, physical and chemical measurement instruments, medical supplies, nutrition supplements, foodstuff, animal feed, and related products in Japan. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-III plus Test Kit for automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. It also provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum; Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for use in detecting type a and type b influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.",
    "website": "http://www.kainos.co.jp",
    "zipcode": null
  },
  "KAN.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "UNIMAT Retirement Community Co.,Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "UNIMAT RETIREM.COMMUNITY",
    "state": null,
    "summary": "UNIMAT Retirement Community Co., Ltd. engages in the nursing care and retirement community businesses in Japan. The company offers nursing care services, such as day service, short stay, home-visit nursing care, home with nursing care, and housing for the elderly with services; meal delivery services; life planning services; recruiting services; and senior service consulting services. It also operates Hotel Allamanda Aoyama in Aoyama, Tokyo; and Allamanda Spa Aoyama Club, as well as restaurants, cafes, spas, fitness, and housing for seniors. In addition, the company processes and sells coffee beans; and developing services for enhancing long-term care operations, and maintains and improves the health of seniors utilizing big data, AI, sensors, etc. The company was formerly known as Unimat Soyokaze Co., Ltd. and changed its name to UNIMAT Retirement Community Co., Ltd. in October 2015. UNIMAT Retirement Community Co., Ltd. was founded in 1974 and is headquartered in Tokyo, Japan.",
    "website": "http://www.unimat-rc.co.jp",
    "zipcode": "107-0061"
  },
  "KIS.F": {
    "city": "Matsumoto",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Kissei Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KISSEI PHARM. LTD",
    "state": null,
    "summary": "Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.",
    "website": "http://www.kissei.co.jp",
    "zipcode": "399-8710"
  },
  "KKPCF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Kaken Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KAKEN PHARMACEUTICAL",
    "state": null,
    "summary": "Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.",
    "website": "http://www.kaken.co.jp",
    "zipcode": "113-8650"
  },
  "KSPHF": {
    "city": "Matsumoto",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Kissei Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KISSEI PHARMACEUTICAL CO",
    "state": null,
    "summary": "Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.",
    "website": "http://www.kissei.co.jp",
    "zipcode": "399-8710"
  },
  "KY4.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kyowa Kirin Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KYOWA KIRIN CO. LTD.",
    "state": null,
    "summary": "Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",
    "website": "http://www.kyowakirin.com",
    "zipcode": "100-0004"
  },
  "KYKOF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Kyowa Kirin Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KYOWA KIRIN CO LTD",
    "state": null,
    "summary": "Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",
    "website": "http://www.kyowakirin.com",
    "zipcode": "100-0004"
  },
  "MAHLY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Distribution",
    "long_name": "MediPal Holdings Corporation",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MEDIPAL HOLDINGS CORP",
    "state": null,
    "summary": "Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business. It also engages in delivering cosmetics, daily necessities, OTC pharmaceuticals, and other products; and animal health products and food processing raw materials wholesale business. In addition, it engages in the provision of cleaning management services; management and operation of distribution centers; planning, management, administration, and product and service development for the Class A dispensing pharmacy service brand; management and marketing support for dispensing pharmacies; and import/export wholesale distribution. Further, it offers health insurance claims review, medical coding dispatch, outsourcing, and remote education services; non-life insurance agency services; medical supply and master product databases for medical facilities; and commissioned delivery and worker dispatch services. The company serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. Medipal Holdings Corporation was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. The company was founded in 1898 and is headquartered in Tokyo, Japan.",
    "website": "http://www.medipal.co.jp",
    "zipcode": "104-8461"
  },
  "MBO.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "MTI Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MTI LTD.",
    "state": null,
    "summary": "MTI Ltd. engages in the content distribution for mobile phones in Japan. It operates Boshimo, an application, which enables digital management of childcare records and other information; Luna-Luna, a women's healthcare-related information Website; Atleta, a condition management system that connects athletes and coaches; and CARADA, a physical data management application, which connects consumers with companies, pharmacies, health examination institutions, and health insurance associations. The company also offers &Pay, a smartphone payment and transfer service; MOBILE CONVERT, a service that optimizes PC Websites for smartphones; and AMY, an artificial intelligence solution, which reduces operational loads of companies. In addition, it provides music.jp, an online store that offers music, movies, TV drama series, animations, books, and comics; Life Ranger, a lifestyle-related information site that provides weather information, maps, train connection information, and navigation functions as a single service; and a site for entertainment services. The company was founded in 1996 and is headquartered in Tokyo, Japan.",
    "website": "http://www.mti.co.jp",
    "zipcode": "163-1435"
  },
  "MFY.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Mochida Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MOCHIDA PHARM.",
    "state": null,
    "summary": "Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.",
    "website": "http://www.mochida.co.jp",
    "zipcode": "162-0845"
  },
  "MJJ.F": {
    "city": "Utsunomiya",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Mani, Inc.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MANI INC.",
    "state": null,
    "summary": "Mani, Inc. engages in the research, development, manufacture, and distribution of medical devices and dental instruments in Japan and internationally. The company offers surgical instruments, such as maniplers, vessel knives, knives, stainless wire needles, and saws used in surgical operations for incision, cutting, and suture; and ophthalmic instruments, including ophthalmic sutures and knives, and trocar kits for eye surgeries, including cataract operations. It also provides surgical eyeless and eyed needles; and dental instruments, such as endodontic instruments, endodontic rotary instruments, root canal obturation, diamond and carbide burs, finishing and polishing instruments, sutures and surgical needles, endodontic micro-accessories, and endodontic accessories. In addition, the company imports and sells medical devices. Mani, Inc. was founded in 1956 and is headquartered in Utsunomiya, Japan.",
    "website": "http://www.mani.co.jp",
    "zipcode": "321-3231"
  },
  "MTHRF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "M3, Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "M3 INC",
    "state": null,
    "summary": "M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates m3.com, a members-only Web site for providing information to the healthcare professionals; and MR-kun that delivers medical and drug information online through m3.com. It also provides MDLinx that offers the review of medical articles and theses in English for physicians in the United States; and MEDI:GATE, which provides various medical news and content, and features online discussion boards where doctors can exchange opinions and communicate with one another in South Korea. In addition, the company offers various Internet-based services for pharmaceutical and other medical-related companies, including marketing support services for medical solution providers and healthcare professionals, clinical trial services, clinical trial support services, market research services, and doctor and pharmacist recruiting support services. Further, it provides services for general public, such as the operation of AskDoctors, a Q and A site to consult doctors through the Internet; Ichie Websites comprising Ichie Breast Cancer and Ichie Menopause, which offers insights and solutions related to breast cancer and menopause; and iTicket Plus, a reservation system for clinics through mobile phones and the Internet. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was founded in 2000 and is headquartered in Tokyo, Japan.",
    "website": "http://corporate.m3.com",
    "zipcode": "107-0052"
  },
  "MTHRY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "M3, Inc.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "M3 INC UNSPN ADS EACH REP 0.5 O",
    "state": null,
    "summary": "M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates m3.com, a members-only Web site for providing information to the healthcare professionals; and MR-kun that delivers medical and drug information online through m3.com. It also provides MDLinx that offers the review of medical articles and theses in English for physicians in the United States; and MEDI:GATE, which provides various medical news and content, and features online discussion boards where doctors can exchange opinions and communicate with one another in South Korea. In addition, the company offers various Internet-based services for pharmaceutical and other medical-related companies, including marketing support services for medical solution providers and healthcare professionals, clinical trial services, clinical trial support services, market research services, and doctor and pharmacist recruiting support services. Further, it provides services for general public, such as the operation of AskDoctors, a Q and A site to consult doctors through the Internet; Ichie Websites comprising Ichie Breast Cancer and Ichie Menopause, which offers insights and solutions related to breast cancer and menopause; and iTicket Plus, a reservation system for clinics through mobile phones and the Internet. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was founded in 2000 and is headquartered in Tokyo, Japan.",
    "website": "http://corporate.m3.com",
    "zipcode": "107-0052"
  },
  "NHNKY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Nihon Kohden Corporation",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "NIHON KOHDEN CORP",
    "state": null,
    "summary": "Nihon Kohden Corporation develops, produces, and sells medical electronic equipment in Japan and internationally. It provides physiological measuring equipment, including electroencephalographs, electrocardiographs, evoked potential and electromyogram measuring systems, and polygraphs for cath labs, as well as diagnostic information systems and related consumables, such as recording papers, electrodes and catheters, and maintenance services. The company also offers patient monitors systems comprising central monitors, bedside monitors, wireless monitors, remote access software, and other equipment; and clinical information systems and related consumables and services, such as electrodes and sensors, and maintenance services. In addition, it provides treatment equipment, which include defibrillators, automated external defibrillators (AED), pacemakers, ventilators, anesthesia machines, cochlear implants, and related consumables and services, such as AED pads and batteries. Further, the company offers other medical equipment, including hematology analyzers, clinical chemistry analyzers, ultrasound diagnostic equipment, and equipment for research and others, as well as consumables, including test reagents, and installation and maintenance services. Nihon Kohden Corporation was founded in 1951 and is headquartered in Tokyo, Japan.",
    "website": "http://www.nihonkohden.com",
    "zipcode": "161-8560"
  },
  "NPPNY": {
    "city": "Kyoto",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nippon Shinyaku Co., Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "NIPPON SHINYAKU CO",
    "state": null,
    "summary": "Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.",
    "website": "http://www.nippon-shinyaku.co.jp",
    "zipcode": "601-8550"
  },
  "OCPNY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Olympus Corporation",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OLYMPUS CORPORATION",
    "state": null,
    "summary": "Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through five segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, Imaging Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, video and other endoscopes system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Imaging Business segment provides digital cameras, IC and voice recorders, mirrorless interchangeable-lens cameras, and interchangeable lenses. The Others segment offers biomedical materials. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and GI- and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.",
    "website": "http://www.olympus-global.com",
    "zipcode": "163-0914"
  },
  "OLY1.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Olympus Corporation",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OLYMPUS CORP.",
    "state": null,
    "summary": "Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through five segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, Imaging Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, video and other endoscopes system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Imaging Business segment provides digital cameras, IC and voice recorders, mirrorless interchangeable-lens cameras, and interchangeable lenses. The Others segment offers biomedical materials. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and GI- and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.",
    "website": "http://www.olympus-global.com",
    "zipcode": "163-0914"
  },
  "OLYS.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Olympus Corporation",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OLYMPUS CORP. ADR",
    "state": null,
    "summary": "Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through five segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, Imaging Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, video and other endoscopes system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Imaging Business segment provides digital cameras, IC and voice recorders, mirrorless interchangeable-lens cameras, and interchangeable lenses. The Others segment offers biomedical materials. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and GI- and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.",
    "website": "http://www.olympus-global.com",
    "zipcode": "163-0914"
  },
  "ON4.MU": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Drug Manufacturers - General",
    "long_name": "Ono Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ONO PHARMACEUT.",
    "state": null,
    "summary": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.",
    "website": "http://www.ono.co.jp",
    "zipcode": "541-8564"
  },
  "OPHLY": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Ono Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ONO PHARMACEUTICAL CO",
    "state": null,
    "summary": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.",
    "website": "http://www.ono.co.jp",
    "zipcode": "541-8564"
  },
  "OS1.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HOLDINGS CO.LTD.",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "OTSKF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HLDGS CO LTD",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "OTSKY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Otsuka Holdings Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "OTSUKA HLDGS CO LTD",
    "state": null,
    "summary": "Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of central nervous system, oncology, cardiovascular system, gastroenterology, ophthalmology, diagnostics, and I.V. solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÃ Jelly, a conditioning food product; BODYMAINTÃ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; OS-1, an oral rehydration solution; HINE E-GEL, a concentrated liquid diet; PROCESSLEAD, a chew and swallow managing food; REHADAYS, a beverage to support exercise and rehabilitation; Oronine H Ointment, a household antiseptic medicine; and vitamin tonics, herbal digestive drinks, and herbal crude drugs. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 2008 and is headquartered in Tokyo, Japan.",
    "website": "http://www.otsuka.com/en",
    "zipcode": "101-0048"
  },
  "PPTDF": {
    "city": "Kawasaki",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "PeptiDream Inc.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "PEPTIDREAM INC",
    "state": null,
    "summary": "PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company uses its Peptide Discovery Platform System platform for the development of peptides. PeptiDream Inc. has a collaboration with Merck & Co. Inc. for the discovery and development of peptide therapeutics capable of neutralizing the SARS-CoV-2 virus (COVID19) and potential coronavirus outbreaks; and a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was founded in 2006 and is headquartered in Kawasaki, Japan.",
    "website": "http://www.peptidream.com",
    "zipcode": "210-0821"
  },
  "SDGCF": {
    "city": "Fuchu",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Sundrug Co.,Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUNDRUG CO LTD",
    "state": null,
    "summary": "Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offers food, cosmetics, home appliances, clothing, car supplies, sports and goods, alcoholic beverages, and pharmaceutical products, as well as fresh food, kerosene, etc. The company was founded in 1957 and is headquartered in Fuchu, Japan.",
    "website": "http://www.sundrug.co.jp",
    "zipcode": "183-0005"
  },
  "SGIOF": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Shionogi & Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SHIONOGI & CO",
    "state": null,
    "summary": "Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with InveniAI, LLC.; Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.",
    "website": "http://www.shionogi.com",
    "zipcode": "541-0045"
  },
  "SGIOY": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Shionogi & Co., Ltd.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SHIONOGI & CO",
    "state": null,
    "summary": "Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.",
    "website": "http://www.shionogi.com",
    "zipcode": "541-0045"
  },
  "SGIPF": {
    "city": "Obu",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Sugi Holdings Co.,Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUGI HOLDINGS CO.LTD.",
    "state": null,
    "summary": "Sugi Holdings Co.,Ltd. operates drugstores in Japan. It also provides visiting nursing services and home care support services. As of June 1, 2019, the company operated 1,190 stores. Sugi Holdings Co.,Ltd. was founded in 1976 and is headquartered in Obu, Japan.",
    "website": "http://www.drug-sugi.co.jp/hd/index.html",
    "zipcode": "474-0011"
  },
  "SH0.F": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Shionogi & Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SHIONOGI + CO. LTD",
    "state": null,
    "summary": "Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with InveniAI, LLC.; Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.",
    "website": "http://www.shionogi.com",
    "zipcode": "541-0045"
  },
  "SNPHY": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Santen Pharmaceutical Co., Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SANTEN PHARMACEUTICAL CO",
    "state": null,
    "summary": "Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.",
    "website": "http://www.santen.com",
    "zipcode": "530-8552"
  },
  "SOLTF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Sosei Group Corporation",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SOSEI GROUP CORP",
    "state": null,
    "summary": "Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of tumors and metastatic castration resistant prostate cancer; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage to treat migraine and other severe headaches; PF-07081532 and PF-07054894, which are in Phase l for use in multiple therapeutic areas; HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial to treat neurological order; GPR35 agonist to treat inflammatory bowel disease; and KY1051, which is in preclinical stage for the treatment of immuno-oncology. It also offers HTL0016878, a muscarinic M4 receptor agonist, which is in Phase I clinical trial for the treatment of Alzheimer's disease; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial to treat endocrine disorders; GLP-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; H4 antagonist, which is in preclinical stage to treat atopic dermatitis; EP4 antagonist, which is in preclinical stage to mediate PGE2 immunosuppression; GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage to treat intestinal disorder; GPR52 agonist to treat of neurology disease; and PAR2 mAb for the treatment of atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab; PeptiDream Inc; Pfizer; AbbVie; Biohaven; GSK; AstraZeneca; Novartis; Genentech; Takeda Pharmaceutical Company Limited; and Metrion Biosciences Limited. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.",
    "website": "http://soseiheptares.com",
    "zipcode": "102-0083"
  },
  "SSMXF": {
    "city": "Kobe",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Sysmex Corporation",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SYSMEX CORP",
    "state": null,
    "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
    "website": "http://www.sysmex.co.jp",
    "zipcode": "651-0073"
  },
  "SSMXY": {
    "city": "Kobe",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Sysmex Corporation",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SYSMEX CORP",
    "state": null,
    "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
    "website": "http://www.sysmex.co.jp",
    "zipcode": "651-0073"
  },
  "SWPIF": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Sawai Group Holdings Co., Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SAWAI PHARMACEUTICAL",
    "state": null,
    "summary": "Sawai Group Holdings Co., Ltd., together with subsidiaries, manufactures, sells, imports, and exports pharmaceutical products in Japan and the United States. The company offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. It serves hospitals, general practitioners, and dispensing pharmacies. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.",
    "website": "http://www.sawai.co.jp",
    "zipcode": "532-0003"
  },
  "SZD.F": {
    "city": "Osaka",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Santen Pharmaceutical Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SANTEN PHARMA.",
    "state": null,
    "summary": "Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.",
    "website": "http://www.santen.com",
    "zipcode": "530-8552"
  },
  "TAIPY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Taisho Pharmaceutical Holdings Co., Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TAISHO PHARMACEUTICAL HLDG CO L",
    "state": null,
    "summary": "Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.",
    "website": "http://www.taisho-holdings.co.jp",
    "zipcode": "170-8655"
  },
  "TAK": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Takeda Pharmaceutical Company L",
    "state": null,
    "summary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.",
    "website": "http://www.takeda.com",
    "zipcode": "103-8668"
  },
  "TAKN.MX": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drugs - Generic",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TAKEDA PHARMACEUTICAL CO LTD",
    "state": null,
    "summary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.",
    "website": "http://www.takeda.com",
    "zipcode": "103-8668"
  },
  "TF2.F": {
    "city": "Kusatsu",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Takara Bio Inc.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TAKARA BIO INC.",
    "state": null,
    "summary": "Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.",
    "website": "http://www.takara-bio.com",
    "zipcode": "525-0058"
  },
  "TKD.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TAKEDA PHARM.CO.LTD.",
    "state": null,
    "summary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.",
    "website": "http://www.takeda.com",
    "zipcode": "103-8668"
  },
  "TKD.VI": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TAKEDA PHARMACEUTICAL CO LTD",
    "state": null,
    "summary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.",
    "website": "http://www.takeda.com",
    "zipcode": "103-8668"
  },
  "TKDA.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TAKEDA PHARM.SPON.ADR/1/2",
    "state": null,
    "summary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.",
    "website": "http://www.takeda.com",
    "zipcode": "103-8668"
  },
  "TKPHF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TAKEDA PHARMACEUTICAL CO LTD",
    "state": null,
    "summary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.",
    "website": "http://www.takeda.com",
    "zipcode": "103-8668"
  },
  "TON.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Toho Holdings Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TOHO HOLDINGS CO. LTD.",
    "state": null,
    "summary": "Toho Holdings Co., Ltd. engages in the wholesale distribution of pharmaceutical products in Japan. It sells prescription pharmaceuticals, reagents, medical devices and materials, OTC drugs, and health foods to preventive care, clinical care, community healthcare linkage, and home medical and nursing care, as well as provides support services, including the development and sale of customer support systems, assistance in the start-up of medical institutions and pharmacies, management consulting services, medical support, and personnel recruitment. The company also engages in dispensing pharmacy business; manufacture and sale of generic drugs; and site management organization business that assists various medical institutions with clinical trials under contract, as well as sells software to medical institutions. In addition, it provides various customer support systems, including ENIF, an information terminal for pharmaceutical ordering; ENI-Pharmacy, a support system for the separation of dispensing and prescribing functions; LXMATE HeLios and SELENE, a medical care appointment system; Appointment service for first patients, a system to make an appointment via medical institute search engine prior to visiting hospital; ENIFwin, an inventory control system for large hospitals, ENIFvoice SP/ ENIFvoice SP + A/ Core, a supporting system for electronic medication history recording with voice recognition; and ENIF Nurse, an operation support terminal for home-visit nurses; and logistics systems. Toho Holdings Co., Ltd. was founded in 1948 and is headquartered in Tokyo, Japan.",
    "website": "http://www.tohohd.co.jp",
    "zipcode": "155-8655"
  },
  "TRUMF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Terumo Corporation",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TERUMO CORP",
    "state": null,
    "summary": "Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, drug-eluting stents, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, flow diverters, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The General Hospital Company segment provides infusion pumps, syringe pumps, solution sets, syringes, I.V. solutions, pain management products, nutritious food, adhesion barriers, blood glucose monitoring systems, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, automated blood collection systems, automated blood component processing systems, pathogen reduction technology, automated centrifugal apheresis systems, cell expansion system, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.",
    "website": "http://www.terumo.co.jp",
    "zipcode": "151-0072"
  },
  "TRUMY": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Terumo Corporation",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TERUMO CORP",
    "state": null,
    "summary": "Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, drug-eluting stents, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, flow diverters, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The General Hospital Company segment provides infusion pumps, syringe pumps, solution sets, syringes, I.V. solutions, pain management products, nutritious food, adhesion barriers, blood glucose monitoring systems, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, automated blood collection systems, automated blood component processing systems, pathogen reduction technology, automated centrifugal apheresis systems, cell expansion system, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.",
    "website": "http://www.terumo.co.jp",
    "zipcode": "151-0072"
  },
  "TSMRF": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Tsumura & Co.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TSUMURA & CO",
    "state": null,
    "summary": "Tsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines, as well as Kampo powdered extracts; and sale of pharmaceuticals and food products. The company was founded in 1893 and is headquartered in Tokyo, Japan.",
    "website": "http://www.tsumura.co.jp",
    "zipcode": "107-8521"
  },
  "TSUSF": {
    "city": "Sapporo",
    "country": "Japan",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Tsuruha Holdings Inc.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TSURUHA HOLDINGS INC",
    "state": null,
    "summary": "Tsuruha Holdings Inc. operates drugstores in Japan. Its drugstores offer medicines and supplements, as well as health, beauty, and diet goods. The company operates approximately 1,600 stores. It also sells products through mail order and online shops. The company was founded in 1929 and is headquartered in Sapporo, Japan.",
    "website": "http://www.tsuruha-hd.co.jp",
    "zipcode": "065-0024"
  },
  "TUO.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Terumo Corporation",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TERUMO CORP.",
    "state": null,
    "summary": "Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, drug-eluting stents, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, flow diverters, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The General Hospital Company segment provides infusion pumps, syringe pumps, solution sets, syringes, I.V. solutions, pain management products, nutritious food, adhesion barriers, blood glucose monitoring systems, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, automated blood collection systems, automated blood component processing systems, pathogen reduction technology, automated centrifugal apheresis systems, cell expansion system, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.",
    "website": "http://www.terumo.co.jp",
    "zipcode": "151-0072"
  },
  "UGI.F": {
    "city": "Obu",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Sugi Holdings Co.,Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUGI HOLDINGS CO. LTD.",
    "state": null,
    "summary": "Sugi Holdings Co.,Ltd. operates drugstores in Japan. It also provides visiting nursing services and home care support services. As of June 1, 2019, the company operated 1,190 stores. Sugi Holdings Co.,Ltd. was founded in 1976 and is headquartered in Obu, Japan.",
    "website": "http://www.drug-sugi.co.jp/hd/index.html",
    "zipcode": "474-0011"
  },
  "YB3.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Shin Nippon Biomedical Laboratories, Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SHIN NIPPON BIOMED.LAB.",
    "state": null,
    "summary": "Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. The company offers pre-clinical laboratory services, such as Good Laboratory Practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. It also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, the company offers site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Tokyo, Japan.",
    "website": "http://www.snbl.co.jp",
    "zipcode": "104-0044"
  },
  "YPH.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA INC.",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "YPHA.F": {
    "city": "Tokyo",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Astellas Pharma Inc.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ASTELLAS PHARMA UNSP.ADR",
    "state": null,
    "summary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.",
    "website": "http://www.astellas.com",
    "zipcode": "103-8411"
  },
  "ZU1.F": {
    "city": "Nagoya",
    "country": "Japan",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Distribution",
    "long_name": "Suzuken Co., Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SUZUKEN CO LTD",
    "state": null,
    "summary": "Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates through four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business segments. The Pharmaceutical Distribution Business segment engages in the procurement and supply of ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research, development, manufacturing, and marketing of pharmaceuticals, as well as diagnostic products focusing on diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as enhances the operations of local pharmacies through training and education. The Healthcare-Related Services Business segment provides manufacturer support services in the form of contract distribution for manufacturers and orphan drugs; and nursing care services, as well as engages in the manufacturing of electrocardiographs, sphygmomanometers, and other medical equipment. The company also publishes medical magazines for medical institutions. Suzuken Co., Ltd. has collaboration with Bushu Pharmaceuticals Ltd. for specialty pharmaceuticals. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.",
    "website": "http://www.suzuken.co.jp",
    "zipcode": "461-8701"
  }
}
